

George Bakris

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7747227/publications.pdf>

Version: 2024-02-01

824
papers

102,628
citations

614

124
h-index

231

305
g-index

864
all docs

864
docs citations

864
times ranked

55936
citing authors

#	ARTICLE	IF	CITATIONS
1	Effectiveness of nonsteroidal mineralocorticoid receptor antagonists in patients with diabetic kidney disease. <i>Postgraduate Medicine</i> , 2023, 135, 224-233.	0.9	13
2	Kidney outcomes with finerenone: an analysis from the FIGARO-DKD study. <i>Nephrology Dialysis Transplantation</i> , 2023, 38, 372-383.	0.4	13
3	Design of the COmbination effect of FInerenone and Empagliflozin in participants with chronic kidney disease and type 2 diabetes using a UACR Endpoint study (CONFIDENCE). <i>Nephrology Dialysis Transplantation</i> , 2023, 38, 894-903.	0.4	48
4	Investigating new treatment opportunities for patients with chronic kidney disease in type 2 diabetes: the role of finerenone. <i>Nephrology Dialysis Transplantation</i> , 2022, 37, 1014-1023.	0.4	50
5	Efficacy and safety of finerenone in patients with chronic kidney disease and type 2 diabetes by <sc>GLP-1 RA</sc> treatment: A subgroup analysis from the <sc>FIDELIO-DKD</sc> trial. <i>Diabetes, Obesity and Metabolism</i> , 2022, 24, 125-134.	2.2	41
6	Successful treatment of refractory HTN with bilateral nephrectomy in a patient with CKD 3. <i>CKJ: Clinical Kidney Journal</i> , 2022, 15, 347-350.	1.4	2
7	Finerenone in Predominantly Advanced CKD and Type 2 Diabetes With or Without Sodium-Glucose Cotransporter-2 Inhibitor Therapy. <i>Kidney International Reports</i> , 2022, 7, 36-45.	0.4	73
8	Mineralocorticoid receptor antagonists in diabetic kidney disease – mechanistic and therapeutic effects. <i>Nature Reviews Nephrology</i> , 2022, 18, 56-70.	4.1	87
9	Cardiovascular and kidney outcomes with finerenone in patients with type 2 diabetes and chronic kidney disease: the FIDELITY pooled analysis. <i>European Heart Journal</i> , 2022, 43, 474-484.	1.0	341
10	Hyperkalemia Risk with Finerenone: Results from the FIDELIO-DKD Trial. <i>Journal of the American Society of Nephrology: JASN</i> , 2022, 33, 225-237.	3.0	89
11	Novel non-steroidal mineralocorticoid receptor antagonists in cardiorenal disease. <i>British Journal of Pharmacology</i> , 2022, 179, 3220-3234.	2.7	65
12	Effects of canagliflozin versus finerenone on cardiorenal outcomes: exploratory <i>post hoc</i> analyses from FIDELIO-DKD compared to reported CREDENCE results. <i>Nephrology Dialysis Transplantation</i> , 2022, 37, 1261-1269.	0.4	32
13	Finerenone Reduces Risk of Incident Heart Failure in Patients With Chronic Kidney Disease and Type 2 Diabetes: Analyses From the FIGARO-DKD Trial. <i>Circulation</i> , 2022, 145, 437-447.	1.6	86
14	Potential Role and Limitations of Estimated Glomerular Filtration Rate Slope Assessment in Cardiovascular Trials. <i>JAMA Cardiology</i> , 2022, 7, 549.	3.0	14
15	Potential Effects of Elimination of the Black Race Coefficient in eGFR Calculations in the CREDENCE Trial. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2022, 17, 361-373.	2.2	9
16	Identifying resistant hypertension in the population: the devil is in the details. <i>Canadian Journal of Cardiology</i> , 2022, . .	0.8	0
17	Novel Renal Autologous Cell Therapy for Type 2 Diabetes Mellitus Chronic Diabetic Kidney Disease: Clinical Trial Design. <i>American Journal of Nephrology</i> , 2022, 53, 50-58.	1.4	5
18	Finerenone in Patients With Chronic Kidney Disease and Type 2 Diabetes According to Baseline HbA1c and Insulin Use: An Analysis From the FIDELIO-DKD Study. <i>Diabetes Care</i> , 2022, 45, e888-e897.	4.3	20

#	ARTICLE	IF	CITATIONS
19	DCRM Multispecialty Practice Recommendations for the management of diabetes, cardiorenal, and metabolic diseases. <i>Journal of Diabetes and Its Complications</i> , 2022, 36, 108101.	1.2	23
20	The impact of canagliflozin on the risk of neuropathy events: A post-hoc exploratory analysis of the CREDENCE trial. <i>Diabetes and Metabolism</i> , 2022, 48, 101331.	1.4	5
21	Effect of the Glucagon-Like Peptide-1 Receptor Agonists Semaglutide and Liraglutide on Kidney Outcomes in Patients With Type 2 Diabetes: Pooled Analysis of SUSTAIN 6 and LEADER. <i>Circulation</i> , 2022, 145, 575-585.	1.6	88
22	10. Cardiovascular Disease and Risk Management: <i>Standards of Medical Care in Diabetes</i> 2022. <i>Diabetes Care</i> , 2022, 45, S144-S174.	4.3	282
23	11. Chronic Kidney Disease and Risk Management: <i>Standards of Medical Care in Diabetes</i> 2022. <i>Diabetes Care</i> , 2022, 45, S175-S184.	4.3	168
24	Modifying chronic kidney disease progression with the mineralocorticoid receptor antagonist finerenone in patients with type 2 diabetes. <i>Diabetes, Obesity and Metabolism</i> , 2022, 24, 1197-1205.	2.2	9
25	Finerenone in patients with chronic kidney disease and type 2 diabetes with and without heart failure: a prespecified subgroup analysis of the FIDELIO-DKD trial. <i>European Journal of Heart Failure</i> , 2022, 24, 996-1005.	2.9	23
26	The FIDELIO Study Podcast. <i>Diabetes Therapy</i> , 2022, , 1.	1.2	0
27	Generalizability of FIGARO-DKD and FIDELIO-DKD Trial Criteria to the US Population Eligible for Finerenone. <i>Journal of the American Heart Association</i> , 2022, 11, e025079.	1.6	7
28	6. Glycemic Targets: <i>Standards of Medical Care in Diabetes</i> 2022. <i>Diabetes Care</i> , 2022, 45, S83-S96.	4.3	388
29	12. Retinopathy, Neuropathy, and Foot Care: <i>Standards of Medical Care in Diabetes</i> 2022. <i>Diabetes Care</i> , 2022, 45, S185-S194.	4.3	87
30	13. Older Adults: <i>Standards of Medical Care in Diabetes</i> 2022. <i>Diabetes Care</i> , 2022, 45, S195-S207.	4.3	114
31	Kidney function assessment and endpoint ascertainment in clinical trials. <i>European Heart Journal</i> , 2022, 43, 1379-1400.	1.0	8
32	Mineralocorticoid Receptor Antagonists in the Treatment of Diabetic Kidney Disease: Their Application in the Era of SGLT2 Inhibitors and GLP-1 Receptor Agonists. <i>Current Diabetes Reports</i> , 2022, 22, 213.	1.7	6
33	Molecular mechanisms and therapeutic targets for diabetic kidney disease. <i>Kidney International</i> , 2022, 102, 248-260.	2.6	112
34	Editorial Cycles and Continuity of <i>Diabetes Care</i> . <i>Diabetes Care</i> , 2022, 45, 1493-1494.	4.3	0
35	Multi-proteomic approach to predict specific cardiovascular events in patients with diabetes and myocardial infarction: findings from the EXAMINE trial. <i>Clinical Research in Cardiology</i> , 2021, 110, 1006-1019.	1.5	23
36	Factitious acidosis and severe hypoalbuminemia caused by unsuspected assay interference. <i>CKJ: Clinical Kidney Journal</i> , 2021, 14, 1023-1024.	1.4	0

#	ARTICLE	IF	CITATIONS
37	Finerenone and Cardiovascular Outcomes in Patients With Chronic Kidney Disease and Type 2 Diabetes. <i>Circulation</i> , 2021, 143, 540-552.	1.6	171
38	Characterization and implications of the initial estimated glomerular filtration rate \hat{eGFR}^{TM} upon sodium-glucose cotransporter-2 inhibition with empagliflozin in the EMPA-REG OUTCOME trial. <i>Kidney International</i> , 2021, 99, 750-762.	2.6	111
39	Insights from CRENDENCE trial indicate an acute drop in estimated glomerular filtration rate during treatment with canagliflozin with implications for clinical practice. <i>Kidney International</i> , 2021, 99, 999-1009.	2.6	93
40	Individual Atrasentan Exposure is Associated With Long-term Kidney and Heart Failure Outcomes in Patients With Type 2 Diabetes and Chronic Kidney Disease. <i>Clinical Pharmacology and Therapeutics</i> , 2021, 109, 1631-1638.	2.3	5
41	Inter-individual variability in atrasentan exposure partly explains variability in kidney protection and fluid retention responses: A post hoc analysis of the SONAR trial. <i>Diabetes, Obesity and Metabolism</i> , 2021, 23, 561-568.	2.2	10
42	Steroidal and non-steroidal mineralocorticoid receptor antagonists in cardiorenal medicine. <i>European Heart Journal</i> , 2021, 42, 152-161.	1.0	249
43	Major adverse renal events (MARE): a proposal to unify renal endpoints. <i>Nephrology Dialysis Transplantation</i> , 2021, 36, 491-497.	0.4	15
44	Kidney, Cardiovascular, and Safety Outcomes of Canagliflozin according to Baseline Albuminuria. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2021, 16, 384-395.	2.2	37
45	Red cell distribution width in patients with diabetes and myocardial infarction: An analysis from the EXAMINE trial. <i>Diabetes, Obesity and Metabolism</i> , 2021, 23, 1580-1587.	2.2	16
46	Effects of canagliflozin on cardiovascular, renal, and safety outcomes in participants with type 2 diabetes and chronic kidney disease according to history of heart failure: Results from the CRENDENCE trial. <i>American Heart Journal</i> , 2021, 233, 141-148.	1.2	30
47	Time in Therapeutic Range. <i>Journal of the American College of Cardiology</i> , 2021, 77, 1300-1301.	1.2	9
48	The effects of canagliflozin on heart failure and cardiovascular death by baseline participant characteristics: Analysis of the CRENDENCE trial. <i>Diabetes, Obesity and Metabolism</i> , 2021, 23, 1652-1659.	2.2	6
49	Influence of sex, age and race on coronary and heart failure events in patients with diabetes and post-acute coronary syndrome. <i>Clinical Research in Cardiology</i> , 2021, 110, 1612-1624.	1.5	14
50	Blood Pressure Effects of Canagliflozin and Clinical Outcomes in Type 2 Diabetes and Chronic Kidney Disease. <i>Circulation</i> , 2021, 143, 1735-1749.	1.6	60
51	Hyperkalemia Management in Older Adults With Diabetic Kidney Disease Receiving Renin-Angiotensin-Aldosterone System Inhibitors: A Post Hoc Analysis of the AMETHYST-DN Clinical Trial. <i>Kidney Medicine</i> , 2021, 3, 360-367.e1.	1.0	2
52	Antisense Inhibition of Angiotensinogen With IONIS-AGT-LRx. <i>JACC Basic To Translational Science</i> , 2021, 6, 485-496.	1.9	30
53	A Non-purine Xanthine Oxidoreductase Inhibitor Reduces Albuminuria in Patients with DKD: A Randomized Controlled Trial. <i>Kidney360</i> , 2021, 2, 1240-1250.	0.9	4
54	Systolic Blood Pressure During Exercise Testing: Where the Valley Means More Than the Peak. <i>Hypertension</i> , 2021, 77, 1915-1917.	1.3	0

#	ARTICLE	IF	CITATIONS
55	Finerenone Reduces New-Onset Atrial Fibrillation in Patients With Chronic Kidney Disease and Type 2 Diabetes. <i>Journal of the American College of Cardiology</i> , 2021, 78, 142-152.	1.2	74
56	Intersection Between Chronic Kidney Disease and Cardiovascular Disease. <i>Current Cardiology Reports</i> , 2021, 23, 117.	1.3	12
57	Effect of KBP-5074 on Blood Pressure in Advanced Chronic Kidney Disease: Results of the BLOCK-CKD Study. <i>Hypertension</i> , 2021, 78, 74-81.	1.3	59
58	Approach to Resistant Hypertension from Cardiology and Nephrology Standpoints. <i>Cardiology Clinics</i> , 2021, 39, 377-387.	0.9	1
59	Effects of canagliflozin on serum potassium in people with diabetes and chronic kidney disease: the CREDENCE trial. <i>European Heart Journal</i> , 2021, 42, 4891-4901.	1.0	80
60	Cardiovascular Events with Finerenone in Kidney Disease and Type 2 Diabetes. <i>New England Journal of Medicine</i> , 2021, 385, 2252-2263.	13.9	599
61	Renal denervation in hypertension patients: Proceedings from an expert consensus roundtable cosponsored by <scp>SCAI</scp> and <scp>NKF</scp>. <i>Catheterization and Cardiovascular Interventions</i> , 2021, 98, 416-426.	0.7	21
62	Early Response in Albuminuria and Long-Term Kidney Protection during Treatment with an Endothelin Receptor Antagonist: A Prespecified Analysis from the SONAR Trial. <i>Journal of the American Society of Nephrology: JASN</i> , 2021, 32, 2900-2911.	3.0	9
63	Response by Filippatos et al to Letter Regarding Article, "Finerenone and Cardiovascular Outcomes in Patients With Chronic Kidney Disease and Type 2 Diabetes". <i>Circulation</i> , 2021, 144, e202-e203.	1.6	7
64	Body weight changes in patients with type 2 diabetes and a recent acute coronary syndrome: an analysis from the EXAMINE trial. <i>Cardiovascular Diabetology</i> , 2021, 20, 187.	2.7	5
65	An evaluation of KBP-5074 in advanced chronic kidney disease with uncontrolled hypertension. <i>Expert Opinion on Investigational Drugs</i> , 2021, 30, 1017-1023.	1.9	10
66	Optimizing Blood Pressure Control Without Adding Anti-Hypertensive Medications. <i>American Journal of Medicine</i> , 2021, 134, 1195-1198.	0.6	0
67	A Lesson From 2020: Public Health Matters for Both COVID-19 and Diabetes. <i>Diabetes Care</i> , 2021, 44, 8-10.	4.3	8
68	Longitudinal Blood Pressure Patterns and Chronic Kidney Disease Progression: An Evolving Paradigm. <i>Hypertension</i> , 2021, 78, 1365-1367.	1.3	0
69	Untreated Hypertension and Subsequent Incidence of Colorectal Cancer: Analysis of a Nationwide Epidemiological Database. <i>Journal of the American Heart Association</i> , 2021, 10, e022479.	1.6	10
70	Cardiovascular Benefits of Angiotensin-Converting Enzyme Inhibition Plus Calcium Channel Blockade in Patients Achieving Tight Blood Pressure Control and With Resistant Hypertension. <i>American Journal of Hypertension</i> , 2021, 34, 531-539.	1.0	1
71	The Effect of Atrasentan on Kidney and Heart Failure Outcomes by Baseline Albuminuria and Kidney Function. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2021, 16, 1824-1832.	2.2	11
72	Blood and Urine Biomarkers Predicting Worsening Kidney Function in Patients with Type 2 Diabetes Post-Acute Coronary Syndrome: An Analysis from the EXAMINE Trial. <i>American Journal of Nephrology</i> , 2021, 52, 969-976.	1.4	8

#	ARTICLE	IF	CITATIONS
73	Mineralocorticoid Receptor Antagonistsâ€™ Evidence for Kidney Protection, Trials With Novel Agents. <i>Advances in Chronic Kidney Disease</i> , 2021, 28, 371-377.	0.6	1
74	Potassium homeostasis and management of dyskalemia in kidney diseases: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference. <i>Kidney International</i> , 2020, 97, 42-61.	2.6	260
75	Approach to the Patient with Hypertensive Nephrosclerosis. , 2020, , 737-752.		1
76	Evaluating the Effects of Canagliflozin on Cardiovascular and Renal Events in Patients With Type 2 Diabetes Mellitus and Chronic Kidney Disease According to Baseline HbA1c, Including Those With HbA1c <7%. <i>Circulation</i> , 2020, 141, 407-410.	1.6	95
77	Clinical and Biomarker Predictors of Expanded Heart Failure Outcomes in Patients With Type 2 Diabetes Mellitus After a Recent Acute Coronary Syndrome: Insights From the EXAMINE Trial. <i>Journal of the American Heart Association</i> , 2020, 9, e012797.	1.6	28
78	Prediction and validation of exenatide risk marker effects on progression of renal disease: Insights from EXSCEL. <i>Diabetes, Obesity and Metabolism</i> , 2020, 22, 798-806.	2.2	11
79	Microvascular and Cardiovascular Outcomes According to Renal Function in Patients Treated With Once-Weekly Exenatide: Insights From the EXSCEL Trial. <i>Diabetes Care</i> , 2020, 43, 446-452.	4.3	63
80	Effects of canagliflozin on anaemia in patients with type 2 diabetes and chronic kidney disease: a post-hoc analysis from the CREDENCE trial. <i>Lancet Diabetes and Endocrinology</i> , the, 2020, 8, 903-914.	5.5	73
81	Diastolic Blood Pressure Does Not Influence Cardiovascular Outcomes in Type 2 Diabetes; or Does It?. <i>Diabetes Care</i> , 2020, 43, 1684-1686.	4.3	2
82	Effects of Canagliflozin in Patients with Baseline eGFR <30 ml/min per 1.73 m2. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2020, 15, 1705-1714.	2.2	87
83	U.S. Prevalence of Individuals With Diabetes and Chronic Kidney Disease Indicated for SGLT-2 Inhibitor Therapy. <i>Journal of the American College of Cardiology</i> , 2020, 76, 2907-2910.	1.2	5
84	Timing of randomization after an acute coronary syndrome in patients with type 2 diabetes mellitus. <i>American Heart Journal</i> , 2020, 229, 40-51.	1.2	4
85	Effect of Finerenone on Chronic Kidney Disease Outcomes in Type 2 Diabetes. <i>New England Journal of Medicine</i> , 2020, 383, 2219-2229.	13.9	1,148
86	An Unusual Case of Resistant Hypertension Secondary to Fibromuscular Dysplasia. <i>JACC: Case Reports</i> , 2020, 2, 2460-2464.	0.3	0
87	Renal, Cardiovascular, and Safety Outcomes of Canagliflozin by Baseline Kidney Function: A Secondary Analysis of the CREDENCE Randomized Trial. <i>Journal of the American Society of Nephrology: JASN</i> , 2020, 31, 1128-1139.	3.0	106
88	Mineralocorticoid Receptor Antagonists for Hypertension Management in Advanced Chronic Kidney Disease. <i>Hypertension</i> , 2020, 76, 144-149.	1.3	27
89	Abnormalities of Potassium in Heart Failure. <i>Journal of the American College of Cardiology</i> , 2020, 75, 2836-2850.	1.2	94
90	Fear of Lowering Cardiovascular Risk by Achieving Blood Pressure Goals. <i>Hypertension</i> , 2020, 75, 943-944.	1.3	0

#	ARTICLE	IF	CITATIONS
91	Association of Arterial Stiffness With Kidney Function Among Adults Without Chronic Kidney Disease. <i>American Journal of Hypertension</i> , 2020, 33, 1003-1010.	1.0	15
92	Reductions in albuminuria with SGLT2 inhibitors: a marker for improved renal outcomes in patients without diabetes?. <i>Lancet Diabetes and Endocrinology</i> , 2020, 8, 553-555.	5.5	7
93	Evolution of Patiromer Use: a Review. <i>Current Cardiology Reports</i> , 2020, 22, 94.	1.3	9
94	Improved Sleep Quality Improves Blood Pressure Control among Patients with Chronic Kidney Disease: A Pilot Study. <i>American Journal of Nephrology</i> , 2020, 51, 249-254.	1.4	6
95	Use of sodium-glucose cotransporter inhibitors in patients with and without type 2 diabetes: implications for incident and prevalent heart failure. <i>European Journal of Heart Failure</i> , 2020, 22, 604-617.	2.9	33
96	Improvement of Cardiovascular Functional Reserve After Kidney Transplant—Has the CAPER Been Solved?. <i>JAMA Cardiology</i> , 2020, 5, 430.	3.0	1
97	Nonsteroidal mineralocorticoid antagonists: Prospects for renoprotection in diabetic kidney disease. <i>Diabetes, Obesity and Metabolism</i> , 2020, 22, 69-76.	2.2	16
98	How to Manage Hypertension in People With Diabetes. <i>American Journal of Hypertension</i> , 2020, 33, 935-943.	1.0	4
99	Hypertension and Diabetes. <i>Endocrinology</i> , 2020, , 109-130.	0.1	0
100	Stemming the Progression of Diabetic Kidney Disease: The Role of the Primary Care Clinician. <i>Journal of Family Practice</i> , 2020, 69, S81-S86.	0.2	0
101	Primary hypertension. , 2019, , 429-437.		0
102	Primary Prevention of ASCVD and T2DM in Patients at Metabolic Risk: An Endocrine Society* Clinical Practice Guideline. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2019, 104, 3939-3985.	1.8	42
103	Canagliflozin and Cardiovascular and Renal Outcomes in Type 2 Diabetes Mellitus and Chronic Kidney Disease in Primary and Secondary Cardiovascular Prevention Groups. <i>Circulation</i> , 2019, 140, 739-750.	1.6	211
104	Major Advancements in Slowing Diabetic Kidney Disease Progression: Focus on SGLT2 Inhibitors. <i>American Journal of Kidney Diseases</i> , 2019, 74, 573-575.	2.1	28
105	Kidney injury is not prevented by hydration alone. <i>European Heart Journal</i> , 2019, 40, 3179-3181.	1.0	2
106	Design and Baseline Characteristics of the Finerenone in Reducing Cardiovascular Mortality and Morbidity in Diabetic Kidney Disease Trial. <i>American Journal of Nephrology</i> , 2019, 50, 345-356.	1.4	127
107	Design and Baseline Characteristics of the Finerenone in Reducing Kidney Failure and Disease Progression in Diabetic Kidney Disease Trial. <i>American Journal of Nephrology</i> , 2019, 50, 333-344.	1.4	112
108	Controversies in the 2017 ACC/AHA Hypertension Guidelines: Who Can Be Eligible for Treatments Under the New Guidelines?—An Asian Perspective. <i>Circulation Journal</i> , 2019, 83, 504-510.	0.7	18

#	ARTICLE	IF	CITATIONS
109	ACC/AHA Versus ESC/ESH on Hypertension Guidelines. Journal of the American College of Cardiology, 2019, 73, 3018-3026.	1.2	193
110	Assessing Wide Pulse Pressure Hypertension. Journal of the American College of Cardiology, 2019, 73, 2856-2858.	1.2	10
111	Blood pressure in chronic kidney disease: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference. Kidney International, 2019, 95, 1027-1036.	2.6	60
112	Heart failure in chronic kidney disease: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference. Kidney International, 2019, 95, 1304-1317.	2.6	232
113	The Management of Hypertension in 2018: What Should the Targets Be?. Current Hypertension Reports, 2019, 21, 41.	1.5	13
114	Barriers to guideline mandated renin-angiotensin inhibitor use: focus on hyperkalaemia. European Heart Journal Supplements, 2019, 21, A20-A27.	0.0	13
115	Atrasentan and renal events in patients with type 2 diabetes and chronic kidney disease (SONAR): a double-blind, randomised, placebo-controlled trial. Lancet, The, 2019, 393, 1937-1947.	6.3	408
116	Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy. New England Journal of Medicine, 2019, 380, 2295-2306.	13.9	3,760
117	Similarities and Differences Between the ACC/AHA and ESH/ESC Guidelines for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults. Circulation Research, 2019, 124, 969-971.	2.0	7
118	Blood Pressure Lowering and Sodium-Glucose Co-transporter 2 Inhibitors (SGLT2is): More Than Osmotic Diuresis. Current Hypertension Reports, 2019, 21, 12.	1.5	48
119	Hypertensive Heart Failure: Sprinting to the Finish Line to Prevent End-Organ Damage. Heart Failure Clinics, 2019, 15, xiii-xv.	1.0	0
120	Paradoxical Cardiorenal Responses Following Acute Vasodilator/Natriuretic Treatment in Presystolic Heart Failure. JACC Basic To Translational Science, 2019, 4, 973-975.	1.9	0
121	Effects of mineralocorticoid receptor antagonists in proteinuric kidney disease. Journal of Hypertension, 2019, 37, 2307-2324.	0.3	66
122	Heart Failure and Changes in Kidney Function. Heart Failure Clinics, 2019, 15, 455-461.	1.0	7
123	Redefining diuretics use in hypertension. Journal of Hypertension, 2019, 37, 1574-1586.	0.3	72
124	The association of interdialytic blood pressure variability with cardiovascular events and all-cause mortality in haemodialysis patients. Nephrology Dialysis Transplantation, 2019, 34, 515-523.	0.4	40
125	Relation of Serum and Urine Renal Biomarkers to Cardiovascular Risk in Patients with Type 2 Diabetes Mellitus and Recent Acute Coronary Syndromes (From the EXAMINE Trial). American Journal of Cardiology, 2019, 123, 382-391.	0.7	12
126	Management of Hypertension in Diabetes Mellitus. , 2019, , 115-133.		0

#	ARTICLE	IF	CITATIONS
127	Hypertension and Diabetes. <i>Endocrinology</i> , 2019, , 1-22.	0.1	0
128	Chronic Kidney Disease in Type 2 Diabetes: Optimizing Glucose-Lowering Therapy. <i>Journal of Family Practice</i> , 2019, 68, S1-S6.	0.2	0
129	Are All Patients With Type 1 Diabetes Destined for Dialysis if They Live Long Enough? Probably Not. <i>Diabetes Care</i> , 2018, 41, 389-390.	4.3	19
130	Hyperuricemia, Acute and Chronic Kidney Disease, Hypertension, and Cardiovascular Disease: Report of a Scientific Workshop Organized by the National Kidney Foundation. <i>American Journal of Kidney Diseases</i> , 2018, 71, 851-865.	2.1	362
131	Long-term efficacy and tolerability of azilsartan medoxomil/chlorthalidone vs olmesartan medoxomil/hydrochlorothiazide in chronic kidney disease. <i>Journal of Clinical Hypertension</i> , 2018, 20, 694-702.	1.0	10
132	Baseline characteristics and enrichment results from the SONAR trial. <i>Diabetes, Obesity and Metabolism</i> , 2018, 20, 1829-1835.	2.2	28
133	Bardoxolone Methyl Improves Kidney Function in Patients with Chronic Kidney Disease Stage 4 and Type 2 Diabetes: Post-Hoc Analyses from Bardoxolone Methyl Evaluation in Patients with Chronic Kidney Disease and Type 2 Diabetes Study. <i>American Journal of Nephrology</i> , 2018, 47, 40-47.	1.4	123
134	A randomized titrate-to-target study comparing fixed-dose combinations of azilsartan medoxomil and chlorthalidone with olmesartan and hydrochlorothiazide in stage-2 systolic hypertension. <i>Journal of Hypertension</i> , 2018, 36, 947-956.	0.3	4
135	Redefining Hypertension – Assessing the New Blood-Pressure Guidelines. <i>New England Journal of Medicine</i> , 2018, 378, 497-499.	13.9	87
136	Kidney Biomarkers and Decline in eGFR in Patients with Type 2 Diabetes. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2018, 13, 398-405.	2.2	28
137	Prior Medications and the Cardiovascular Benefits From Combination Angiotensin-Converting Enzyme Inhibition Plus Calcium Channel Blockade Among High-Risk Hypertensive Patients. <i>Journal of the American Heart Association</i> , 2018, 7, .	1.6	8
138	Rationale and protocol of the Study Of diabetic Nephropathy with AtRasentan (SONAR) trial: A clinical trial design novel to diabetic nephropathy. <i>Diabetes, Obesity and Metabolism</i> , 2018, 20, 1369-1376.	2.2	60
139	Results of ACCORDIAN in ACCORD with lower blood pressure begetting lower mortality in patients with diabetes. <i>Diabetes, Obesity and Metabolism</i> , 2018, 20, 1335-1336.	2.2	5
140	Blood Pressure Control and Cardiovascular/Renal Outcomes. <i>Endocrinology and Metabolism Clinics of North America</i> , 2018, 47, 175-184.	1.2	8
141	SGLT2 Inhibitors and Mechanisms of Hypertension. <i>Current Cardiology Reports</i> , 2018, 20, 1.	1.3	78
142	Novel therapies for diabetic kidney disease. <i>Kidney International Supplements</i> , 2018, 8, 18-25.	4.6	37
143	Sodium/Glucose Cotransporter 2 Inhibitors in Patients With Diabetes Mellitus and Chronic Kidney Disease. <i>Circulation</i> , 2018, 137, 130-133.	1.6	7
144	Update on reducing the development of diabetic kidney disease and cardiovascular death in diabetes. <i>Kidney International Supplements</i> , 2018, 8, 1.	4.6	4

#	ARTICLE	IF	CITATIONS
145	Individualizing Blood Pressure Targets for People With Diabetes and Hypertension. JAMA - Journal of the American Medical Association, 2018, 319, 1319.	3.8	48
146	Blood pressure reduced to new guideline goals in patients with high-normal glucose further reduces cardiovascular events. Journal of Clinical Hypertension, 2018, 20, 625-626.	1.0	1
147	Diabetic Kidney Disease: A Determinant of Cardiovascular Risk in Type 1 Diabetes. Diabetes Care, 2018, 41, 662-663.	4.3	10
148	Prevalent and Incident Heart Failure in Cardiovascular Outcome Trials of Patients With Type 2 Diabetes. Journal of the American College of Cardiology, 2018, 71, 1379-1390.	1.2	50
149	MY APPROACH to the elderly patient with resistant hypertension. Trends in Cardiovascular Medicine, 2018, 28, 79-80.	2.3	0
150	High-sensitivity C-reactive protein, low-density lipoprotein cholesterol and cardiovascular outcomes in patients with type 2 diabetes in the EXAMINE (Examination of) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 54 Metabolism, 2018, 20, 654-659.	2.2	30
151	Effect of Patiomer on Hyperkalemia Recurrence in Older Chronic Kidney Disease Patients Taking RAAS Inhibitors. American Journal of Medicine, 2018, 131, 555-564.e3.	0.6	38
152	Consequences of Overinterpreting Serum Creatinine Increases when Achieving BP Reduction. Clinical Journal of the American Society of Nephrology: CJASN, 2018, 13, 9-10.	2.2	6
153	Use of Combination Therapies. , 2018, , 261-267.		0
154	MASKed-unconTrolled hypERTension management based on office BP or on ambulatory blood pressure measurement (MASTER) Study: a randomised controlled trial protocol. BMJ Open, 2018, 8, e021038.	0.8	33
155	Creatinine Bump Following Antihypertensive Therapy. Hypertension, 2018, 72, 1274-1276.	1.3	11
156	Intradialytic Hypotension: Is Midodrine the Answer?. American Journal of Nephrology, 2018, 48, 378-380.	1.4	3
157	Ambulatory Blood Pressure Monitoring. JAMA - Journal of the American Medical Association, 2018, 320, 1807.	3.8	7
158	Efficacy of a novel inhibitor of vascular adhesion protein-1 in reducing albuminuria in patients with diabetic kidney disease (ALBUM): a randomised, placebo-controlled, phase 2 trial. Lancet Diabetes and Endocrinology,the, 2018, 6, 925-933.	5.5	30
159	Has the Sun Set on Nighttime Dosing in Uncomplicated Hypertension?. Hypertension, 2018, 72, 836-838.	1.3	10
160	Average Clinician-Measured Blood Pressures and Cardiovascular Outcomes in Patients With Type 2 Diabetes Mellitus and Ischemic Heart Disease in the EXAMINE Trial. Journal of the American Heart Association, 2018, 7, e009114.	1.6	19
161	Initial single-pill combinations for antihypertensive treatment: greater cardiovascular mortality reduction yet still not used. European Heart Journal, 2018, 39, 3662-3663.	1.0	1
162	Resistant Hypertension: Detection, Evaluation, and Management: A Scientific Statement From the American Heart Association. Hypertension, 2018, 72, e53-e90.	1.3	629

#	ARTICLE	IF	CITATIONS
163	Presence of Diabetes Does Not Mandate Lower Blood Pressure to Reduce Cardiovascular Events. Journal of the American College of Cardiology, 2018, 72, 1224-1226.	1.2	0
164	Perspective on the New Blood-Pressure Guidelines. European Heart Journal, 2018, 39, 3008-3009.	1.0	5
165	Long-term effects of patiomer for hyperkalaemia treatment in patients with mild heart failure and diabetic nephropathy on angiotensin-converting enzymes/angiotensin receptor blockers: results from AMETHYST-DN. ESC Heart Failure, 2018, 5, 592-602.	1.4	45
166	Hyperkalaemia in diabetes: a silent risk predicting poor outcomes. Diabetic Medicine, 2018, 35, 1049-1050.	1.2	0
167	Early and Chronic Dipeptidyl Peptidase-IV Inhibition and Cardiovascular Events in Patients With Type 2 Diabetes Mellitus After an Acute Coronary Syndrome: A Landmark Analysis of the EXAMINE Trial. Journal of the American Heart Association, 2018, 7, .	1.6	9
168	Cardiovascular and Renal Outcomes With Canagliflozin According to Baseline Kidney Function. Circulation, 2018, 138, 1537-1550.	1.6	200
169	Big Topics for Diabetes Care in 2018: Clinical Guidelines, Costs of Diabetes, and Information Technology. Diabetes Care, 2018, 41, 1327-1329.	4.3	4
170	The Renin-Angiotensin-Aldosterone System and the Kidney. , 2018, , 27-41.		3
171	Hypertension and Diabetes. Endocrinology, 2018, , 1-22.	0.1	0
172	Hypertension and Chronic Kidney Disease. , 2018, , 311-320.		1
173	Approach to Difficult to Manage Primary Hypertension. , 2018, , 281-287.		2
174	Comparison of Effectiveness of Azilsartan Medoxomil and Olmesartan in Blacks Versus Whites With Systemic Hypertension. American Journal of Cardiology, 2018, 122, 1496-1505.	0.7	6
175	Renal denervation: one step backwards, three steps forward. Nature Reviews Nephrology, 2018, 14, 602-604.	4.1	5
176	FO022BARDOXOLONE METHYL PREVENTS EGFR DECLINE IN PATIENTS WITH CHRONIC KIDNEY DISEASE STAGE 4 AND TYPE 2 DIABETES - POST-HOC ANALYSES FROM BEACON. Nephrology Dialysis Transplantation, 2018, 33, i10-i10.	0.4	2
177	Diabetes Mellitus and Hypertension. Updates in Hypertension and Cardiovascular Protection, 2018, , 695-704.	0.1	1
178	Hypertension and Diabetes. Endocrinology, 2018, , 109-130.	0.1	0
179	Catheter-Based Renal Denervation for Resistant Hypertension: Will It Ever Be Ready for "Prime Time"? American Journal of Hypertension, 2017, 30, 841-846.	1.0	3
180	Relationship of glycated haemoglobin and reported hypoglycaemia to cardiovascular outcomes in patients with type 2 diabetes and recent acute coronary syndrome events: EXAMINE trial. Diabetes, Obesity and Metabolism, 2017, 19, 664-671.	2.2	53

#	ARTICLE	IF	CITATIONS
181	<i>Diabetes Care</i> : "Taking It to the Limit One More Time" <i>Diabetes Care</i> , 2017, 40, 3-6.	4.3	7
182	Hypertension control and cardiovascular disease " Authors' reply. <i>Lancet</i> , The, 2017, 389, 154-155.	6.3	1
183	Searching for the Optimal Blood Pressure Range in the Elderly. <i>Journal of the American College of Cardiology</i> , 2017, 69, 494-496.	1.2	1
184	Resistant Hypertension. <i>Hypertension</i> , 2017, 69, 582-583.	1.3	3
185	Serial Measurement of High-Sensitivity Troponin I and Cardiovascular Outcomes in Patients With Type 2 Diabetes Mellitus in the EXAMINE Trial (Examination of Cardiovascular Outcomes With Alogliptin) <i>TJ ETQq1 1 0.784314 rg54/Overlaid</i>	1.0	1
186	Response by Bakris to Letter Regarding Article, "The Implications of Blood Pressure Measurement Methods on Treatment Targets for Blood Pressure" <i>Circulation</i> , 2017, 135, e47.	1.6	3
187	Evaluation of the angiotensin II receptor blocker azilsartan medoxomil in African-American patients with hypertension. <i>Journal of Clinical Hypertension</i> , 2017, 19, 695-701.	1.0	6
188	Acute Declines in Renal Function during Intensive BP Lowering: Implications for Future ESRD Risk. <i>Journal of the American Society of Nephrology: JASN</i> , 2017, 28, 2794-2801.	3.0	37
189	Mineralocorticoid antagonists in chronic kidney disease. <i>Current Opinion in Nephrology and Hypertension</i> , 2017, 26, 50-55.	1.0	24
190	Renal Targeted Therapies of Antihypertensive and Cardiovascular Drugs for Patients With Stages 3 Through 5d Kidney Disease. <i>Clinical Pharmacology and Therapeutics</i> , 2017, 102, 450-458.	2.3	11
191	Nonsteroidal mineralocorticoid antagonists in diabetic kidney disease. <i>Current Opinion in Nephrology and Hypertension</i> , 2017, 26, 368-374.	1.0	19
192	AVERAGE CLINICIAN MEASURED BLOOD PRESSURE PREDICT CARDIOVASCULAR OUTCOMES IN PATIENTS WITH TYPE 2 DIABETES FOLLOWING ACUTE CORONARY SYNDROMES IN THE EXAMINE TRIAL. <i>Journal of the American College of Cardiology</i> , 2017, 69, 1676.	1.2	1
193	Sustained Reduction of Blood Pressure With Baroreceptor Activation Therapy. <i>Hypertension</i> , 2017, 69, 836-843.	1.3	96
194	An exploratory propensity score matched comparison of second-generation and first-generation baroreflex activation therapy systems. <i>Journal of the American Society of Hypertension</i> , 2017, 11, 81-91.	2.3	23
195	On-Treatment Blood Pressure and Cardiovascular Outcomes in Older Adults With Isolated Systolic Hypertension. <i>Hypertension</i> , 2017, 69, 220-227.	1.3	33
196	Differentiation of Diabetes by Pathophysiology, Natural History, and Prognosis. <i>Diabetes</i> , 2017, 66, 241-255.	0.3	454
197	Olmesartan-based monotherapy vs combination therapy in hypertension: A meta-analysis based on age and chronic kidney disease status. <i>Journal of Clinical Hypertension</i> , 2017, 19, 1309-1318.	1.0	4
198	Diabetes and Hypertension: A Position Statement by the American Diabetes Association. <i>Diabetes Care</i> , 2017, 40, 1273-1284.	4.3	462

#	ARTICLE	IF	CITATIONS
199	Initial Single-Pill Blood Pressure-Lowering Therapy: Should It Be for Most People?. Journal of the American Heart Association, 2017, 6, .	1.6	3
200	Severe menses-associated hypertension successfully treated with gonadotropin-releasing hormone agonist. Journal of Clinical Hypertension, 2017, 19, 1202-1203.	1.0	1
201	High screen failure rate in patients with resistant hypertension: Findings from SYMPLICITY HTN-3. American Heart Journal, 2017, 192, 76-84.	1.2	3
202	Impact of eplerenone on cardiovascular outcomes in heart failure patients with hypokalaemia. European Journal of Heart Failure, 2017, 19, 792-799.	2.9	34
203	BP Control and Long-Term Risk of ESRD and Mortality. Journal of the American Society of Nephrology: JASN, 2017, 28, 671-677.	3.0	71
204	The Kidney in Hypertension. Medical Clinics of North America, 2017, 101, 207-217.	1.1	23
205	The Canagliflozin and Renal Endpoints in Diabetes with Established Nephropathy Clinical Evaluation (CRENDENCE) Study Rationale, Design, and Baseline Characteristics. American Journal of Nephrology, 2017, 46, 462-472.	1.4	194
206	Differences in Dynamic Diurnal Blood Pressure Variability Between Japanese and American Treatment-Resistant Hypertensive Populations. Circulation Journal, 2017, 81, 1337-1345.	0.7	25
207	Effects of azilsartan medoxomil compared with olmesartan and valsartan on ambulatory and clinic blood pressure in patients with type 2 diabetes and prediabetes. Journal of Hypertension, 2016, 34, 788-797.	0.3	26
208	New approaches to hyperkalemia in patients with indications for renin angiotensin aldosterone inhibitors: Considerations for trial design and regulatory approval. International Journal of Cardiology, 2016, 216, 46-51.	0.8	20
209	Masked and Nocturnal Hypertension in the ARTS-DN ABPM Sub-Study with Finerenone. Journal of the American Society of Hypertension, 2016, 10, e7.	2.3	8
210	Blood pressure goals in T2DM – time for a rethink?. Nature Reviews Endocrinology, 2016, 12, 629-630.	4.3	1
211	Cardiovascular Outcomes According to Systolic Blood Pressure in Patients With and Without Diabetes: An ACCOMPLISH Substudy. Journal of Clinical Hypertension, 2016, 18, 299-307.	1.0	26
212	Reduced blood pressure-lowering effect of catheter-based renal denervation in patients with isolated systolic hypertension: data from SYMPLICITY HTN-3 and the Global SYMPLICITY Registry. European Heart Journal, 2016, 38, ehw325.	1.0	104
213	The Implications of Blood Pressure Measurement Methods on Treatment Targets for Blood Pressure. Circulation, 2016, 134, 904-905.	1.6	62
214	Angiotensin-Converting Enzyme Inhibitor Use and Major Cardiovascular Outcomes in Type 2 Diabetes Mellitus Treated With the Dipeptidyl Peptidase 4 Inhibitor Alogliptin. Hypertension, 2016, 68, 606-613.	1.3	21
215	Relationship Between Obesity, Hypertension, and Aldosterone Production in Postmenopausal African American Women: A Pilot Study. Journal of Clinical Hypertension, 2016, 18, 1216-1221.	1.0	10
216	Impact of Renal Denervation on Patients With Obstructive Sleep Apnea and Resistant Hypertension – Insights From the SYMPLICITY HTN-3 Trial. Circulation Journal, 2016, 80, 1404-1412.	0.7	64

#	ARTICLE	IF	CITATIONS
217	Diabetes Care: "Lagniappe" and "Seeing Is Believing". Diabetes Care, 2016, 39, 1069-1071.	4.3	1
218	Current Status of Renal Denervation in Hypertension. Current Cardiology Reports, 2016, 18, 107.	1.3	3
219	New Onset Hypertension Linked to Generic Cyclosporine Substitution in Post-Renal Transplant Patient. American Journal of Nephrology, 2016, 44, 219-223.	1.4	3
220	SGLT2 inhibitors might halt progression of diabetic nephropathy. Nature Reviews Nephrology, 2016, 12, 583-584.	4.1	5
221	Effect of Sitagliptin on Kidney Function and Respective Cardiovascular Outcomes in Type 2 Diabetes: Outcomes From TECOS. Diabetes Care, 2016, 39, 2304-2310.	4.3	142
222	Cardiovascular Risk Assessment, Summary of Guidelines for the Management of Hypertension and a Critical Appraisal of the 2014 Expert Panel of the National Institutes of Health Report. , 2016, , 131-150.		0
223	Regression to the Mean in SYMPPLICITY-HTN-3. Journal of the American College of Cardiology, 2016, 68, 2016-2025.	1.2	50
224	Intensive Hemodialysis, Left Ventricular Hypertrophy, and Cardiovascular Disease. American Journal of Kidney Diseases, 2016, 68, S5-S14.	2.1	112
225	Intensive Hemodialysis, Blood Pressure, and Antihypertensive Medication Use. American Journal of Kidney Diseases, 2016, 68, S15-S23.	2.1	37
226	Intensive Hemodialysis and Potential Risks With Increasing Treatment. American Journal of Kidney Diseases, 2016, 68, S51-S58.	2.1	27
227	Treatment with patiomer decreases aldosterone in patients with chronic kidney disease and hyperkalemia on renin-angiotensin system inhibitors. Kidney International, 2016, 90, 696-704.	2.6	55
228	Should Restrictions Be Relaxed for Metformin Use in Chronic Kidney Disease? Yes, They Should Be Relaxed! What's the Fuss?. Diabetes Care, 2016, 39, 1287-1291.	4.3	27
229	Cardiovascular Mortality in Patients With Type 2 Diabetes and Recent Acute Coronary Syndromes From the EXAMINE Trial. Diabetes Care, 2016, 39, 1267-1273.	4.3	47
230	Renal Denervation: a Field in Flux. Current Hypertension Reports, 2016, 18, 56.	1.5	3
231	Hydrochlorothiazide as the Diuretic of Choice for Hypertension. Journal of the American College of Cardiology, 2016, 67, 390-391.	1.2	4
232	Finerenone for Albuminuria in Patients With Diabetic Nephropathy—Reply. JAMA - Journal of the American Medical Association, 2016, 315, 306.	3.8	4
233	Management of Hypertension in Diabetic Nephropathy: How Low Should We Go?. Blood Purification, 2016, 41, 139-143.	0.9	22
234	Has RAAS Blockade Reached Its Limits in the Treatment of Diabetic Nephropathy?. Current Diabetes Reports, 2016, 16, 24.	1.7	21

#	ARTICLE	IF	CITATIONS
235	From epidemiological transition to modern cardiovascular epidemiology: hypertension in the 21st century. <i>Lancet, The</i> , 2016, 388, 530-532.	6.3	63
236	Ischemic cardiac outcomes and hospitalizations according to prior macrovascular disease status in patients with type 2 diabetes and recent acute coronary syndrome from the Examination of Cardiovascular Outcomes with Alogliptin versus Standard of Care trial. <i>American Heart Journal</i> , 2016, 175, 18-27.	1.2	6
237	Effect of Naltrexone-Bupropion on Major Adverse Cardiovascular Events in Overweight and Obese Patients With Cardiovascular Risk Factors. <i>JAMA - Journal of the American Medical Association</i> , 2016, 315, 990.	3.8	182
238	SGLT2 inhibitors: not just another glucose-lowering agent. <i>Nature Reviews Nephrology</i> , 2016, 12, 128-129.	4.1	2
239	Carotid Baroreceptor Stimulation. <i>Updates in Hypertension and Cardiovascular Protection</i> , 2016, , 339-348.	0.1	1
240	Effect of patiomer on reducing serum potassium and preventing recurrent hyperkalaemia in patients with heart failure and chronic kidney disease on <sc>RAAS</sc> inhibitors. <i>European Journal of Heart Failure</i> , 2015, 17, 1057-1065.	2.9	134
241	A clinician's perspective of the role of renal sympathetic nerves in hypertension. <i>Frontiers in Physiology</i> , 2015, 6, 75.	1.3	6
242	New insights into cardiovascular risk factors and outcomes. <i>Nature Reviews Nephrology</i> , 2015, 11, 70-72.	4.1	13
243	Design Considerations for Clinical Trials of Autonomic Modulation Therapies Targeting Hypertension and Heart Failure. <i>Hypertension</i> , 2015, 65, 5-15.	1.3	27
244	Effect of Catheter-Based Renal Denervation on Morning and Nocturnal Blood Pressure. <i>Hypertension</i> , 2015, 66, 1130-1137.	1.3	42
245	Renal denervation for the treatment of resistant hypertension: review and clinical perspective. <i>American Journal of Physiology - Renal Physiology</i> , 2015, 309, F583-F594.	1.3	47
246	Correlations of plasma renin activity and aldosterone concentration with ambulatory blood pressure responses to nebivolol and valsartan, alone and in combination, in hypertension. <i>Journal of the American Society of Hypertension</i> , 2015, 9, 845-854.	2.3	15
247	Hypertension and new treatment approaches targeting the sympathetic nervous system. <i>Current Opinion in Pharmacology</i> , 2015, 21, 20-24.	1.7	16
248	Efficacy and safety of perindopril arginine + amlodipine in hypertension. <i>Journal of the American Society of Hypertension</i> , 2015, 9, 266-274.	2.3	11
249	Renal Denervation After SYMPPLICITY HTN-3: Where Do We Go?. <i>Canadian Journal of Cardiology</i> , 2015, 31, 642-648.	0.8	11
250	Renal Denervation Therapy and Baroreceptor Activation Therapy: Emerging Tools for Treating Resistant Hypertension. , 2015, , 163-183.		0
251	Renal Denervation for Resistant Hypertension and Beyond. <i>Advances in Chronic Kidney Disease</i> , 2015, 22, 133-139.	0.6	4
252	Blood Pressure Reduction: An Added Benefit of Sodiumâ€“Glucose Cotransporter 2 Inhibitors in Patients With Type 2 Diabetes. <i>Diabetes Care</i> , 2015, 38, 429-430.	4.3	99

#	ARTICLE	IF	CITATIONS
253	Effect of Patiromer on Serum Potassium Level in Patients With Hyperkalemia and Diabetic Kidney Disease. JAMA - Journal of the American Medical Association, 2015, 314, 151.	3.8	370
254	Update on Blood Pressure Goals in Diabetes Mellitus. Current Cardiology Reports, 2015, 17, 37.	1.3	6
255	Reply. Journal of the American College of Cardiology, 2015, 65, 959-960.	1.2	3
256	New Agents for Hyperkalemia. New England Journal of Medicine, 2015, 372, 1569-1572.	13.9	6
257	Endothelin Antagonism and Hypertension: An Evolving Target. Seminars in Nephrology, 2015, 35, 168-175.	0.6	17
258	Heart failure and mortality outcomes in patients with type 2 diabetes taking alogliptin versus placebo in EXAMINE: a multicentre, randomised, double-blind trial. Lancet, The, 2015, 385, 2067-2076.	6.3	659
259	12-Month Blood Pressure Results of Catheter-Based Renal Artery Denervation for Resistant Hypertension. Journal of the American College of Cardiology, 2015, 65, 1314-1321.	1.2	103
260	Impact of blood pressure lowering in type 2 diabetes. Nature Reviews Nephrology, 2015, 11, 320-321.	4.1	2
261	Spirolactone for resistant hypertensionâ€”hard to resist?. Lancet, The, 2015, 386, 2032-2034.	6.3	11
262	Effects of aliskiren in diabetic and non-diabetic patients with coronary artery disease: Insights from AQUARIUS. Atherosclerosis, 2015, 243, 553-559.	0.4	3
263	An analysis of the blood pressure and safety outcomes to renal denervation in African Americans and Non-African Americans in the SYMPPLICITY HTN-3 trial. Journal of the American Society of Hypertension, 2015, 9, 769-779.	2.3	36
264	Patiromer induces rapid and sustained potassium lowering in patients with chronic kidney disease and hyperkalemia. Kidney International, 2015, 88, 1427-1433.	2.6	90
265	Status of <i>Diabetes Care</i>: New Challenges, New Concepts, New Measuresâ€”Focusing on the Future!. Diabetes Care, 2015, 38, 1177-1180.	4.3	5
266	Summary and Conclusions. High Blood Pressure and Cardiovascular Prevention, 2015, 22, 23-23.	1.0	1
267	The double challenge of resistant hypertension and chronic kidney disease. Lancet, The, 2015, 386, 1588-1598.	6.3	147
268	Hypertension Management in Diabetic Kidney Disease. Diabetes Spectrum, 2015, 28, 175-180.	0.4	26
269	New Potassium Binders for the Treatment of Hyperkalemia. Hypertension, 2015, 66, 731-738.	1.3	63
270	Effect of Finerenone on Albuminuria in Patients With Diabetic Nephropathy. JAMA - Journal of the American Medical Association, 2015, 314, 884.	3.8	523

#	ARTICLE	IF	CITATIONS
271	Racial impact of diurnal variations in blood pressure on cardiovascular events in chronic kidney disease. <i>Journal of the American Society of Hypertension</i> , 2015, 9, 299-306.	2.3	9
272	Advances in treatment of hyperkalemia in chronic kidney disease. <i>Expert Opinion on Pharmacotherapy</i> , 2015, 16, 2205-2215.	0.9	31
273	Blood-Pressure Control. <i>New England Journal of Medicine</i> , 2015, 373, 2180-2182.	13.9	2
274	Predictors of blood pressure response in the SYMPLICITY HTN-3 trial. <i>European Heart Journal</i> , 2015, 36, 219-227.	1.0	458
275	Patiomer in Patients with Kidney Disease and Hyperkalemia Receiving RAAS Inhibitors. <i>New England Journal of Medicine</i> , 2015, 372, 211-221.	13.9	521
276	Approach to the Patient with Hypertensive Nephrosclerosis. , 2015, , 455-469.		0
277	The Future of Interventional Management of Hypertension: Threats and Opportunities. <i>Current Vascular Pharmacology</i> , 2014, 12, 69-76.	0.8	9
278	Renal Denervation for Resistant Hypertension. <i>New England Journal of Medicine</i> , 2014, 371, 182-184.	13.9	33
279	Rationale, Design, and Baseline Characteristics of ARTS-DN: A Randomized Study to Assess the Safety and Efficacy of Finerenone in Patients with Type 2 Diabetes Mellitus and a Clinical Diagnosis of Diabetic Nephropathy. <i>American Journal of Nephrology</i> , 2014, 40, 572-581.	1.4	33
280	Status of Diabetes Care: "It Just Doesn't Get Any Better . . . or Does It?" <i>Diabetes Care</i> , 2014, 37, 1782-1785.		5
281	Efficacy and Safety of Canagliflozin in Patients with Type 2 Diabetes and Stage 3 Nephropathy. <i>American Journal of Nephrology</i> , 2014, 40, 64-74.	1.4	106
282	Mechanisms Contributing to Adverse Cardiovascular Events in Patients with Type 2 Diabetes Mellitus and Stage 4 Chronic Kidney Disease Treated with Bardoxolone Methyl. <i>American Journal of Nephrology</i> , 2014, 39, 499-508.	1.4	124
283	Orthostatic Hypotension Associated With Baroreceptor Dysfunction: Treatment Approaches. <i>Journal of Clinical Hypertension</i> , 2014, 16, 141-148.	1.0	22
284	Sympathetic Activation in Resistant Hypertension: Theory and Therapy. <i>Seminars in Nephrology</i> , 2014, 34, 550-559.	0.6	12
285	Clinical Practice Guidelines for the Management of Hypertension in the Community. <i>Journal of Clinical Hypertension</i> , 2014, 16, 14-26.	1.0	768
286	The Future of Renal Denervation in Resistant Hypertension. <i>Current Hypertension Reports</i> , 2014, 16, 494.	1.5	16
287	Effects of combining azilsartan medoxomil with amlodipine in patients with stage 2 hypertension. <i>Blood Pressure Monitoring</i> , 2014, 19, 90-97.	0.4	10
288	Early Patterns of Blood Pressure Change and Future Coronary Atherosclerosis. <i>JAMA - Journal of the American Medical Association</i> , 2014, 311, 471.	3.8	7

#	ARTICLE	IF	CITATIONS
289	Evidence-Based Triple Antihypertensive Therapy Yields Lower Mortality in Older Patients With Diabetes Mellitus. <i>Hypertension</i> , 2014, 63, 220-221.	1.3	2
290	The Role of Aldosterone in the Spectrum of Cardiovascular and Kidney Disease Risk: Introduction. <i>Seminars in Nephrology</i> , 2014, 34, 245-246.	0.6	0
291	Effects of antihypertensive treatment in Asian populations: A meta-analysis of prospective randomized controlled studies (CARDiovascular protection group in Asia: CARNA). <i>Journal of the American Society of Hypertension</i> , 2014, 8, 103-116.	2.3	22
292	CaseBook Challenges: Managing Gout, Hyperuricemia and Comorbiditiesâ€”Dialogue with the Experts. <i>American Journal of Medicine</i> , 2014, 127, S1.	0.6	3
293	Renal Denervation and LeftÂVentricular Mass Regression. <i>Journal of the American College of Cardiology</i> , 2014, 63, 1924-1925.	1.2	13
294	Review of blood pressure control rates and outcomes. <i>Journal of the American Society of Hypertension</i> , 2014, 8, 127-141.	2.3	55
295	Metformin nephrotoxicity insights: Will they change clinical management? (<i>Journal of the American Society of Nephrology</i> , 2014, 6, 111-112.	0.8	6
296	Diabetic Kidney Disease: A Report From an ADA ConsensusÂConference. <i>American Journal of Kidney Diseases</i> , 2014, 64, 510-533.	2.1	439
297	Renin inhibition in patients with chronic kidney disease: Is it conclusively non-indicated?. <i>JRAAS - Journal of the Renin-Angiotensin-Aldosterone System</i> , 2014, 15, 97-98.	1.0	3
298	Risk Factors for Heart Failure in Patients With Type 2 Diabetes Mellitus and Stage 4 Chronic Kidney Disease Treated With Bardoxolone Methyl. <i>Journal of Cardiac Failure</i> , 2014, 20, 953-958.	0.7	139
299	Diabetic Kidney Disease: A Report From an ADA Consensus Conference. <i>Diabetes Care</i> , 2014, 37, 2864-2883.	4.3	781
300	Incidence, Determinants, and Prognostic Significance of Hyperkalemia and Worsening Renal Function in Patients With Heart Failure Receiving the Mineralocorticoid Receptor Antagonist Eplerenone or Placebo in Addition to Optimal Medical Therapy. <i>Circulation: Heart Failure</i> , 2014, 7, 51-58.	1.6	203
301	Detection, evaluation, and treatment of severe and resistant hypertension. <i>Journal of the American Society of Hypertension</i> , 2014, 8, 743-757.	2.3	45
302	Sorafenib Dose Escalation Is Not Uniformly Associated With Blood Pressure Elevations in Normotensive Patients With Advanced Malignancies. <i>Clinical Pharmacology and Therapeutics</i> , 2014, 96, 27-35.	2.3	11
303	Microalbuminuria as a Risk Predictor in Diabetes: The Continuing Saga. <i>Diabetes Care</i> , 2014, 37, 867-875.	4.3	151
304	The Contribution of the ACCOMPLISH Trial to the Treatment of Stage 2 Hypertension. <i>Current Hypertension Reports</i> , 2014, 16, 419.	1.5	5
305	Blood Pressure, Hypertension, RAAS Blockade, and Drug Therapy in Diabetic Kidney Disease. <i>Advances in Chronic Kidney Disease</i> , 2014, 21, 281-286.	0.6	51
306	Prediction and Management of Hyperkalemia Across the Spectrum of Chronic Kidney Disease. <i>Seminars in Nephrology</i> , 2014, 34, 333-339.	0.6	128

#	ARTICLE	IF	CITATIONS
307	A Controlled Trial of Renal Denervation for Resistant Hypertension. <i>New England Journal of Medicine</i> , 2014, 370, 1393-1401.	13.9	1,848
308	Impact of Renal Denervation on 24-Hour Ambulatory Blood Pressure. <i>Journal of the American College of Cardiology</i> , 2014, 64, 1071-1078.	1.2	164
309	Blood pressure effects of sodium-glucose co-transport 2 (SGLT2) inhibitors. <i>Journal of the American Society of Hypertension</i> , 2014, 8, 330-339.	2.3	201
310	Predictors and outcomes of resistant hypertension among patients with coronary artery disease and hypertension. <i>Journal of Hypertension</i> , 2014, 32, 635-643.	0.3	88
311	Diagnosis, Prevention, and Treatment of Hypertensive Heart Disease. , 2014, , 51-58.		1
312	Rationale and Trial Design of Bardoxolone Methyl Evaluation in Patients with Chronic Kidney Disease and Type 2 Diabetes: The Occurrence of Renal Events (BEACON). <i>American Journal of Nephrology</i> , 2013, 37, 212-222.	1.4	82
313	Chronic Kidney Disease as a Coronary Artery Disease Risk Equivalent. <i>Current Cardiology Reports</i> , 2013, 15, 340.	1.3	120
314	Role of Ambulatory Blood Pressure Monitoring in Hypertension and Diabetes. <i>Current Hypertension Reports</i> , 2013, 15, 137-142.	1.5	3
315	Systolic Blood Pressure and Cardiovascular Outcomes During Treatment of Hypertension. <i>American Journal of Medicine</i> , 2013, 126, 501-508.	0.6	56
316	Resistant hypertension—its identification and epidemiology. <i>Nature Reviews Nephrology</i> , 2013, 9, 51-58.	4.1	162
317	Alogliptin after Acute Coronary Syndrome in Patients with Type 2 Diabetes. <i>New England Journal of Medicine</i> , 2013, 369, 1327-1335.	13.9	2,261
318	International Expert Consensus Statement. <i>Journal of the American College of Cardiology</i> , 2013, 62, 2031-2045.	1.2	124
319	Comparison of Benazepril Plus Amlodipine or Hydrochlorothiazide in High-Risk Patients With Hypertension and Coronary Artery Disease. <i>American Journal of Cardiology</i> , 2013, 112, 255-259.	0.7	25
320	Effects of Nebivolol on Aortic Compliance in Patients With Diabetes and Maximal Renin Angiotensin System Blockade: The <sc>EFFORT</sc> Study. <i>Journal of Clinical Hypertension</i> , 2013, 15, 473-479.	1.0	15
321	Effects of body size and hypertension treatments on cardiovascular event rates: subanalysis of the ACCOMPLISH randomised controlled trial. <i>Lancet</i> , The, 2013, 381, 537-545.	6.3	132
322	The past, present and future of renin-angiotensin aldosterone system inhibition. <i>International Journal of Cardiology</i> , 2013, 167, 1677-1687.	0.8	97
323	Kidney Disease in Hypertension. , 2013, , 270-279.		0
324	Noninsulin glucose-lowering agents for the treatment of patients on dialysis. <i>Nature Reviews Nephrology</i> , 2013, 9, 147-153.	4.1	27

#	ARTICLE	IF	CITATIONS
325	Lowering blood pressure limits in patients with type 2 diabetes: Is it still warranted?. Journal of Diabetes and Its Complications, 2013, 27, 415-416.	1.2	0
326	Association of Race and Body Mass Index With ESRD and Mortality in CKD Stages 3-4: Results From the Kidney Early Evaluation Program (KEEP). American Journal of Kidney Diseases, 2013, 61, 404-412.	2.1	42
327	Obesity, blood pressure, and cardiovascular outcomes – Authors' reply. Lancet, The, 2013, 381, 1982-1983.	6.3	0
328	Efficacy and Safety of Canagliflozin (CANA) in Subjects with Type 2 Diabetes Mellitus (T2DM) and Chronic Kidney Disease (CKD) Over 52 Weeks. Canadian Journal of Diabetes, 2013, 37, S27.	0.4	3
329	Randomized Study of Antihypertensive Efficacy and Safety of Combination Aliskiren/Valsartan vs Valsartan Monotherapy in Hypertensive Participants With Type 2 Diabetes Mellitus. Journal of Clinical Hypertension, 2013, 15, 92-100.	1.0	32
330	Recognition and management of masked hypertension: A review and novel approach. Journal of the American Society of Hypertension, 2013, 7, 244-252.	2.3	33
331	KDOQI US Commentary on the 2012 KDIGO Clinical Practice Guideline for Management of Blood Pressure in CKD. American Journal of Kidney Diseases, 2013, 62, 201-213.	2.1	174
332	Antihypertensive efficacy of the angiotensin receptor blocker azilsartan medoxomil compared with the angiotensin-converting enzyme inhibitor ramipril. Journal of Human Hypertension, 2013, 27, 479-486.	1.0	44
333	Indications for renal denervation: a balanced approach?. Nature Reviews Cardiology, 2013, 10, 434-436.	6.1	4
334	Bardoxolone Methyl in Type 2 Diabetes and Stage 4 Chronic Kidney Disease. New England Journal of Medicine, 2013, 369, 2492-2503.	13.9	844
335	The OSCAR for cardiovascular disease prevention in chronic kidney disease goes to blood pressure control. Kidney International, 2013, 83, 20-22.	2.6	5
336	Blood pressure goals in T2DM: a Latin American perspective. Nature Reviews Endocrinology, 2013, 9, 138-139.	4.3	1
337	Effect of Aliskiren on Progression of Coronary Disease in Patients With Prehypertension. JAMA - Journal of the American Medical Association, 2013, 310, 1135.	3.8	67
338	A Trial of 2 Strategies to Reduce Nocturnal Blood Pressure in Blacks With Chronic Kidney Disease. Hypertension, 2013, 61, 82-88.	1.3	82
339	Complete Renin–Angiotensin–Aldosterone System (RAAS) Blockade in High-Risk Patients. Hypertension, 2013, 62, 444-449.	1.3	9
340	Effects of Vascular Endothelial Growth Factor Signaling Inhibition on Human Erythropoiesis. Oncologist, 2013, 18, 965-970.	1.9	12
341	Association of BP Variability with Mortality among African Americans with CKD. Clinical Journal of the American Society of Nephrology: CJASN, 2013, 8, 731-738.	2.2	55
342	Rationale for Establishing a Mechanism to Increase Reimbursement to Hypertension Specialists. Journal of Clinical Hypertension, 2013, 15, 397-403.	1.0	7

#	ARTICLE	IF	CITATIONS
343	Baseline characteristics in the Bardoxolone methyl Evaluation in patients with Chronic kidney disease and type 2 diabetes mellitus: the Occurrence of renal events (BEACON) trial. <i>Nephrology Dialysis Transplantation</i> , 2013, 28, 2841-2850.	0.4	21
344	Optimal blood pressure for kidney disease—lower is not better. <i>Nature Reviews Nephrology</i> , 2013, 9, 634-635.	4.1	3
345	Determinants and Changes Associated with Aldosterone Breakthrough after Angiotensin II Receptor Blockade in Patients with Type 2 Diabetes with Overt Nephropathy. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2013, 8, 1694-1701.	2.2	30
346	Both Chronic Kidney Disease and Nocturnal Blood Pressure Associate with Strokes in the Elderly. <i>American Journal of Nephrology</i> , 2013, 38, 195-203.	1.4	11
347	Resistant hypertension: a frequent and ominous finding among hypertensive patients with atherothrombosis. <i>European Heart Journal</i> , 2013, 34, 1204-1214.	1.0	167
348	Efficacy of baroreflex activation therapy for the treatment of resistant hypertension. <i>EuroIntervention</i> , 2013, 9, R136-R139.	1.4	4
349	Blood Pressure Components and End-stage Renal Disease in Persons With Chronic Kidney Disease. <i>Archives of Internal Medicine</i> , 2012, 172, 41.	4.3	112
350	Use of a Single Target Blood Pressure Level in Type 2 Diabetes Mellitus for All Cardiovascular Risk Reduction. <i>Archives of Internal Medicine</i> , 2012, 172, 1304.	4.3	6
351	Renal outcomes in hypertensive Black patients at high cardiovascular risk. <i>Kidney International</i> , 2012, 81, 568-576.	2.6	31
352	Mineralocorticoid receptor antagonists for heart failure with reduced ejection fraction: integrating evidence into clinical practice. <i>European Heart Journal</i> , 2012, 33, 2782-2795.	1.0	148
353	Azilsartan Medoxomil Plus Chlorthalidone Reduces Blood Pressure More Effectively Than Olmesartan Plus Hydrochlorothiazide in Stage 2 Systolic Hypertension. <i>Hypertension</i> , 2012, 60, 310-318.	1.3	59
354	Approaches for targeting blood pressure control in sleep disorders. <i>Current Opinion in Nephrology and Hypertension</i> , 2012, 21, 469-474.	1.0	5
355	A reappraisal of renin-angiotensin system blockade on microalbuminuria development. <i>Journal of Hypertension</i> , 2012, 30, 48-50.	0.3	2
356	Pros and Cons of Aggressive Blood Pressure Lowering in Patients with Type 2 Diabetes. <i>Current Vascular Pharmacology</i> , 2012, 10, 156-161.	0.8	16
357	Should ambulatory blood pressure monitoring be mandatory for future studies in resistant hypertension. <i>Journal of Hypertension</i> , 2012, 30, 874-876.	0.3	49
358	Author's reply: Inadequate sleep equates to inadequate BP control. <i>Nature Reviews Cardiology</i> , 2012, 9, 429-429.	6.1	0
359	New insights—from risk factors to treatment implications. <i>Nature Reviews Cardiology</i> , 2012, 9, 75-77.	6.1	6
360	Management of Hypertension in the Elderly Population. <i>Journals of Gerontology - Series A Biological Sciences and Medical Sciences</i> , 2012, 67, 1343-1351.	1.7	19

#	ARTICLE	IF	CITATIONS
361	Lipid Disorders in Uremia and Dialysis. Contributions To Nephrology, 2012, 178, 100-105.	1.1	21
362	Chronic kidney disease: a coronary heart disease equivalent?. Lancet, The, 2012, 380, 783-785.	6.3	10
363	Baroreflex Activation Therapy provides durable benefit in patients with resistant hypertension: results of long-term follow-up in the Rheos Pivotal Trial. Journal of the American Society of Hypertension, 2012, 6, 152-158.	2.3	212
364	Predictors of systolic BP <140 mmHg and systolic BP level by randomly assigned treatment group (benazepril plus amlodipine or hydrochlorothiazide) in the ACCOMPLISH Study. Blood Pressure, 2012, 21, 82-87.	0.7	4
365	Management of cardiac toxicity in patients receiving vascular endothelial growth factor signaling pathway inhibitors. American Heart Journal, 2012, 163, 156-163.	1.2	108
366	Renin-Angiotensin Inhibition in Systolic Heart Failure and Chronic Kidney Disease. American Journal of Medicine, 2012, 125, 399-410.	0.6	69
367	Awareness of Kidney Disease and Relationship to End-stage Renal Disease and Mortality. American Journal of Medicine, 2012, 125, 661-669.	0.6	53
368	Antihypertensive Efficacy of Hydrochlorothiazide vs Chlorthalidone Combined with Azilsartan Medoxomil. American Journal of Medicine, 2012, 125, 1229.e1-1229.e10.	0.6	71
369	Antihypertensive Therapy and New-Onset Diabetes. , 2012, , 121-127.		0
370	Novel Pharmacological Approaches in Hypertension Treatment. , 2012, , 175-184.		0
371	Combination Therapy in Hypertension Treatment. , 2012, , 169-182.		1
372	Hypertensive Goals in Patients with Coronary Artery Disease. Current Cardiology Reports, 2012, 14, 667-672.	1.3	0
373	Timing and Efficacy of Alternative Methods of Sympathetic Blockade. Current Hypertension Reports, 2012, 14, 455-461.	1.5	12
374	Primary hypertension. , 2012, , 437-443.		1
375	Catheter-Based Renal Denervation for Resistant Hypertension: Rationale and Design of the SYMPPLICITY HTN-3 Trial. Clinical Cardiology, 2012, 35, 528-535.	0.7	278
376	Effects of combining simvastatin with rosiglitazone on inflammation, oxidant stress and ambulatory blood pressure in patients with the metabolic syndrome: the SIROCO study. Diabetes, Obesity and Metabolism, 2012, 14, 181-186.	2.2	18
377	Single-Pill Combination of Telmisartan/Amlodipine Versus Amlodipine Monotherapy in Diabetic Hypertensive Patients: An 8-Week Randomized, Parallel-Group, Double-Blind Trial. Clinical Therapeutics, 2012, 34, 537-551.	1.1	17
378	Using an Established Telehealth Model to Train Urban Primary Care Providers on Hypertension Management. Journal of Clinical Hypertension, 2012, 14, 45-50.	1.0	26

#	ARTICLE	IF	CITATIONS
379	Blood Pressure—Lowering Efficacy of the Fixed-Dose Combination of Azilsartan Medoxomil and Chlorthalidone: A Factorial Study. <i>Journal of Clinical Hypertension</i> , 2012, 14, 284-292.	1.0	41
380	The promise of renal denervation. <i>Cleveland Clinic Journal of Medicine</i> , 2012, 79, 498-500.	0.6	17
381	Effects of the Angiotensin Receptor Blocker Azilsartan Medoxomil Versus Olmesartan and Valsartan on Ambulatory and Clinic Blood Pressure in Patients With Stages 1 and 2 Hypertension. <i>Hypertension</i> , 2011, 57, 413-420.	1.3	192
382	Renal function and target organ damage in hypertension. <i>European Heart Journal</i> , 2011, 32, 1599-1604.	1.0	81
383	Recognition, Pathogenesis, and Treatment of Different Stages of Nephropathy in Patients With Type 2 Diabetes Mellitus. <i>Mayo Clinic Proceedings</i> , 2011, 86, 444-456.	1.4	104
384	ACCF/AHA 2011 Expert Consensus Document on Hypertension in the Elderly. <i>Journal of the American College of Cardiology</i> , 2011, 57, 2037-2114.	1.2	419
385	Baroreflex Activation Therapy Lowers Blood Pressure in Patients With Resistant Hypertension. <i>Journal of the American College of Cardiology</i> , 2011, 58, 765-773.	1.2	538
386	Assessment and management of vascular disease risk in patients with chronic kidney disease. <i>Journal of Clinical Lipidology</i> , 2011, 5, 251-260.	0.6	0
387	Epidemiology of hypertensive kidney disease. <i>Nature Reviews Nephrology</i> , 2011, 7, 11-21.	4.1	113
388	EXamination of Cardiovascular Outcomes with AlogliptIN versus Standard of Care in Patients with Type 2 Diabetes Mellitus and Acute Coronary Syndrome (EXAMINE). <i>American Heart Journal</i> , 2011, 162, 620-626.e1.	1.2	138
389	ACCF/AHA 2011 Expert Consensus Document on Hypertension in the Elderly. <i>Journal of the American Society of Hypertension</i> , 2011, 5, 259-352.	2.3	125
390	Newer renin-angiotensin-aldosterone system blocker combinations. <i>Current Opinion in Nephrology and Hypertension</i> , 2011, 20, 471-475.	1.0	2
391	Combination Therapy in Hypertension. <i>Journal of Clinical Hypertension</i> , 2011, 13, 146-154.	1.0	114
392	CON: Blood Pressure Treatment Goal for Patients With Diabetes Should Be $\leq 130/80\text{ mm Hg}$. <i>Journal of Clinical Hypertension</i> , 2011, 13, 263-265.	1.0	5
393	The Comparative Effects of Azilsartan Medoxomil and Olmesartan on Ambulatory and Clinic Blood Pressure. <i>Journal of Clinical Hypertension</i> , 2011, 13, 81-88.	1.0	127
394	Blood Pressure Targets in Diabetes: Is This the Time for Change?—CON (Rebuttal). <i>Journal of Clinical Hypertension</i> , 2011, 13, 268-269.	1.0	1
395	Leadership Message. <i>Journal of Clinical Hypertension</i> , 2011, 13, 533-533.	1.0	0
396	Comparison of the Novel Angiotensin II Receptor Blocker Azilsartan Medoxomil vs Valsartan by Ambulatory Blood Pressure Monitoring. <i>Journal of Clinical Hypertension</i> , 2011, 13, 467-472.	1.0	100

#	ARTICLE	IF	CITATIONS
397	The United Nations High Level Meeting Addresses Noncommunicable Diseases, But Where Is Hypertension?. <i>Journal of Clinical Hypertension</i> , 2011, 13, 787-790.	1.0	4
398	Comparison of the CKD Epidemiology Collaboration (CKD-EPI) and Modification of Diet in Renal Disease (MDRD) Study Equations: Risk Factors for and Complications of CKD and Mortality in the Kidney Early Evaluation Program (KEEP). <i>American Journal of Kidney Diseases</i> , 2011, 57, S9-S16.	2.1	116
399	Comparison of the CKD Epidemiology Collaboration (CKD-EPI) and Modification of Diet in Renal Disease (MDRD) Study Equations: Prevalence of and Risk Factors for Diabetes Mellitus in CKD in the Kidney Early Evaluation Program (KEEP). <i>American Journal of Kidney Diseases</i> , 2011, 57, S24-S31.	2.1	28
400	Sustainable Community-Based CKD Screening Methods Employed by the National Kidney Foundation's Kidney Early Evaluation Program (KEEP). <i>American Journal of Kidney Diseases</i> , 2011, 57, S4-S8.	2.1	25
401	National Kidney Foundation's Kidney Early Evaluation Program (KEEP) Annual Data Report 2010: Executive Summary. <i>American Journal of Kidney Diseases</i> , 2011, 57, S1-S3.	2.1	8
402	Comparison of Measured GFR, Serum Creatinine, Cystatin C, and Beta-Trace Protein to Predict ESRD in African Americans With Hypertensive CKD. <i>American Journal of Kidney Diseases</i> , 2011, 58, 886-893.	2.1	74
403	Effects of Naproxen on Blood Pressure in Patients With Osteoarthritis. <i>American Journal of Cardiology</i> , 2011, 107, 1338-1345.	0.7	16
404	Blood Pressure Targets for Patients with Diabetes or Kidney Disease. <i>Current Hypertension Reports</i> , 2011, 13, 452-455.	1.5	17
405	Do fibrates truly preserve kidney function?. <i>Nature Reviews Endocrinology</i> , 2011, 7, 130-131.	4.3	4
406	Guidelines and Recommendations for Laboratory Analysis in the Diagnosis and Management of Diabetes Mellitus. <i>Clinical Chemistry</i> , 2011, 57, e1-e47.	1.5	583
407	Executive Summary: Guidelines and Recommendations for Laboratory Analysis in the Diagnosis and Management of Diabetes Mellitus. <i>Clinical Chemistry</i> , 2011, 57, 793-798.	1.5	104
408	Endothelin Antagonism in Patients with Resistant Hypertension and Hypertension Nephropathy. <i>Contributions To Nephrology</i> , 2011, 172, 223-234.	1.1	10
409	Isolated Diastolic Hypotension and Incident Heart Failure in Older Adults. <i>Hypertension</i> , 2011, 58, 895-901.	1.3	44
410	ACCF/AHA 2011 Expert Consensus Document on Hypertension in the Elderly. <i>Circulation</i> , 2011, 123, 2434-2506.	1.6	381
411	Efficacy and Duration of Benazepril Plus Amlodipine or Hydrochlorothiazide on 24-Hour Ambulatory Systolic Blood Pressure Control. <i>Hypertension</i> , 2011, 57, 174-179.	1.3	55
412	Diabetic Cardiovascular Disease Predicts Chronic Kidney Disease Awareness in the Kidney Early Evaluation Program. <i>CardioRenal Medicine</i> , 2011, 1, 45-52.	0.7	17
413	Interaction between Adiponectin and Aldosterone. <i>CardioRenal Medicine</i> , 2011, 1, 96-101.	0.7	31
414	The Association between Parathyroid Hormone Levels and the Cardiorenal Metabolic Syndrome in Non-Diabetic Chronic Kidney Disease. <i>CardioRenal Medicine</i> , 2011, 1, 123-130.	0.7	11

#	ARTICLE	IF	CITATIONS
415	Guidelines and Recommendations for Laboratory Analysis in the Diagnosis and Management of Diabetes Mellitus. <i>Diabetes Care</i> , 2011, 34, e61-e99.	4.3	389
416	Position Statement Executive Summary: Guidelines and Recommendations for Laboratory Analysis in the Diagnosis and Management of Diabetes Mellitus. <i>Diabetes Care</i> , 2011, 34, 1419-1423.	4.3	138
417	Cardiovascular Risk Assessment and Summary of Guidelines for the Management of Hypertension. , 2011, , 97-113.		1
418	Telmisartan in incipient and overt diabetic renal disease. <i>Journal of Nephrology</i> , 2011, 24, 263-273.	0.9	12
419	Executive Summary: Guidelines and Recommendations for Laboratory Analysis in the Diagnosis and Management of Diabetes Mellitus. <i>Laboratory Medicine Online</i> , 2011, 1, 173.	0.0	0
420	The role of nitric oxide in improving endothelial function and cardiovascular health: focus on nebivolol. <i>Cardiovascular Therapy and Prevention (Russian Federation)</i> , 2011, 10, 116-121.	0.4	0
421	2010 ACCF/AHA/AATS/ACR/ASA/SCA/SCAI/SIR/STS/SVM Guidelines for the Diagnosis and Management of Patients with Thoracic Aortic Disease. <i>Anesthesia and Analgesia</i> , 2010, 111, 279-315.	1.1	116
422	Fixed-dose combination and chronic kidney disease progression: which is the best?. <i>Current Opinion in Nephrology and Hypertension</i> , 2010, 19, 450-455.	1.0	6
423	Optimal Blood Pressure for a Patient with Type 2 Diabetes Mellitus: Insight from the ACCORD Study. <i>Current Hypertension Reports</i> , 2010, 12, 313-315.	1.5	4
424	Prevalence of CKD and Comorbid Illness in Elderly Patients in the United States: Results From the Kidney Early Evaluation Program (KEEP). <i>American Journal of Kidney Diseases</i> , 2010, 55, S23-S33.	2.1	230
425	Racial Differences in Kidney Function Among Individuals With Obesity and Metabolic Syndrome: Results From the Kidney Early Evaluation Program (KEEP). <i>American Journal of Kidney Diseases</i> , 2010, 55, S4-S14.	2.1	19
426	National Kidney Foundation's Kidney Early Evaluation Program (KEEP) Annual Data Report 2009: Executive Summary. <i>American Journal of Kidney Diseases</i> , 2010, 55, S1-S3.	2.1	160
427	Obesity is associated with increased parathyroid hormone levels independent of glomerular filtration rate in chronic kidney disease. <i>Metabolism: Clinical and Experimental</i> , 2010, 59, 385-389.	1.5	24
428	Are There Effects of Renin-angiotensin System Antagonists Beyond Blood Pressure Control?. <i>American Journal of Cardiology</i> , 2010, 105, 21A-29A.	0.7	44
429	Dysglycemia Predicts Cardiovascular and Kidney Disease in the Kidney Early Evaluation Program. <i>Journal of Clinical Hypertension</i> , 2010, 12, 51-58.	1.0	29
430	Prevention of Microalbuminuria in Patients With Type 2 Diabetes: What Do We Know?. <i>Journal of Clinical Hypertension</i> , 2010, 12, 422-430.	1.0	17
431	Predictors of Hypertension Control in a Diverse General Cardiology Practice. <i>Journal of Clinical Hypertension</i> , 2010, 12, 570-577.	1.0	18
432	Hypertension Following Kidney Injury. <i>Journal of Clinical Hypertension</i> , 2010, 12, 727-730.	1.0	3

#	ARTICLE	IF	CITATIONS
433	Effect of Combining Extended-Release Carvedilol and Lisinopril in Hypertension: Results of the COSMOS Study. <i>Journal of Clinical Hypertension</i> , 2010, 12, 678-686.	1.0	23
434	Leadership Message. <i>Journal of Clinical Hypertension</i> , 2010, 12, 631-632.	1.0	0
435	Limitations of metformin use in patients with kidney disease: are they warranted?. <i>Diabetes, Obesity and Metabolism</i> , 2010, 12, 1079-1083.	2.2	41
436	Cardiovascular risk modification in participants with coronary disease screened by the Kidney Early Evaluation Program. <i>Internal Medicine Journal</i> , 2010, 40, 833-841.	0.5	6
437	Hypertensive Kidney Disease. , 2010, , 57-67.		0
438	Forging Ahead with Lessons from the Past. <i>American Journal of Nephrology</i> , 2010, 31, H.	1.4	0
439	Pheochromocytoma in Pregnancy. <i>Hypertension</i> , 2010, 55, 600-606.	1.3	98
440	Hypokalemia and Outcomes in Patients With Chronic Heart Failure and Chronic Kidney Disease. <i>Circulation: Heart Failure</i> , 2010, 3, 253-260.	1.6	123
441	Management of High Blood Pressure in Blacks. <i>Hypertension</i> , 2010, 56, 780-800.	1.3	398
442	Malnutrition-Inflammation Modifies the Relationship of Cholesterol with Cardiovascular Disease. <i>Journal of the American Society of Nephrology: JASN</i> , 2010, 21, 2131-2142.	3.0	43
443	Tight Blood Pressure Control and Cardiovascular Outcomes Among Hypertensive Patients With Diabetes and Coronary Artery Disease. <i>JAMA - Journal of the American Medical Association</i> , 2010, 304, 61.	3.8	578
444	2010 ACCF/AHA/AATS/ACR/ASA/SCA/SCAI/SIR/STS/SVM Guidelines for the Diagnosis and Management of Patients With Thoracic Aortic Disease. <i>Circulation</i> , 2010, 121, e266-369.	1.6	1,994
445	Divergent Results Using Clinic and Ambulatory Blood Pressures. <i>Hypertension</i> , 2010, 56, 824-830.	1.3	169
446	Gestational Diabetes Mellitus Alone in the Absence of Subsequent Diabetes Is Associated With Microalbuminuria. <i>Diabetes Care</i> , 2010, 33, 2586-2591.	4.3	38
447	Initial Assessment, Surveillance, and Management of Blood Pressure in Patients Receiving Vascular Endothelial Growth Factor Signaling Pathway Inhibitors. <i>Journal of the National Cancer Institute</i> , 2010, 102, 596-604.	3.0	381
448	Overview of the KEEP international articles. <i>Kidney International</i> , 2010, 77, S1.	2.6	0
449	<i>CYP3A4</i> and <i>CYP3A5</i> Polymorphisms and Blood Pressure Response to Amlodipine among African-American Men and Women with Early Hypertensive Renal Disease. <i>American Journal of Nephrology</i> , 2010, 31, 95-103.	1.4	47
450	Editorial Perspective. Should Microalbuminuria Ever Be Considered as a Renal Endpoint in Any Clinical Trial. <i>American Journal of Nephrology</i> , 2010, 31, 469-470.	1.4	24

#	ARTICLE	IF	CITATIONS
451	Dual RAAS blockade is desirable in kidney disease: Con. <i>Kidney International</i> , 2010, 78, 546-549.	2.6	13
452	24-Hour Ambulatory Blood Pressure in the ACCOMPLISH Trial. <i>New England Journal of Medicine</i> , 2010, 363, 98-98.	13.9	26
453	Masked hypertension: a risk factor in children with CKD. <i>Nature Reviews Nephrology</i> , 2010, 6, 132-134.	4.1	3
454	Blood pressure target for renoprotection in children. <i>Nature Reviews Nephrology</i> , 2010, 6, 67-68.	4.1	3
455	Prehypertension: is it relevant for nephrologists?. <i>Kidney International</i> , 2010, 77, 194-200.	2.6	40
456	National Kidney Foundation consensus conference on cardiovascular and kidney diseases and diabetes risk: an integrated therapeutic approach to reduce events. <i>Kidney International</i> , 2010, 78, 726-736.	2.6	48
457	Lower Blood Pressure Goals in High-Risk Cardiovascular Patients: Are They Defensible?. <i>Cardiology Clinics</i> , 2010, 28, 447-452.	0.9	2
458	Treatment and Control of High Blood Pressure in Adults. <i>Cardiology Clinics</i> , 2010, 28, 609-622.	0.9	29
459	Hypertensive nephropathy: prevention and treatment recommendations. <i>Expert Opinion on Pharmacotherapy</i> , 2010, 11, 2675-2686.	0.9	61
460	Preface. <i>Cardiology Clinics</i> , 2010, 28, xi.	0.9	0
461	Intensive Blood-Pressure Control in Hypertensive Chronic Kidney Disease. <i>New England Journal of Medicine</i> , 2010, 363, 918-929.	13.9	638
462	2010 ACCF/AHA/AATS/ACR/ASA/SCA/SCAI/SIR/STS/SVM Guidelines for the Diagnosis and Management of Patients With Thoracic Aortic Disease. <i>Journal of the American College of Cardiology</i> , 2010, 55, e27-e129.	1.2	1,298
463	Cardiovascular Events During Differing Hypertension Therapies in Patients With Diabetes. <i>Journal of the American College of Cardiology</i> , 2010, 56, 77-85.	1.2	215
464	Oral potassium supplement use and outcomes in chronic heart failure: A propensity-matched study. <i>International Journal of Cardiology</i> , 2010, 141, 167-174.	0.8	26
465	Association between hyperuricemia and incident heart failure among older adults: A propensity-matched study. <i>International Journal of Cardiology</i> , 2010, 142, 279-287.	0.8	92
466	Mild hyperkalemia and outcomes in chronic heart failure: A propensity matched study. <i>International Journal of Cardiology</i> , 2010, 144, 383-388.	0.8	48
467	Corrigendum to "A propensity-matched study of low serum potassium and mortality in older adults with chronic heart failure" [Int. J. Cardiol. 137 (2009) 1-8]. <i>International Journal of Cardiology</i> , 2010, 145, 409.	0.8	1
468	The Role of Nitric Oxide in Improving Endothelial Function and Cardiovascular Health: Focus on Nebivolol. <i>American Journal of Medicine</i> , 2010, 123, S2-S8.	0.6	12

#	ARTICLE	IF	CITATIONS
469	The Role of Vasodilating $\hat{1}^2$ -Blockers in Patients with Hypertension and the Cardiometabolic Syndrome. American Journal of Medicine, 2010, 123, S21-S26.	0.6	24
470	Pathogenesis and Clinical Physiology of Hypertension. Cardiology Clinics, 2010, 28, 545-559.	0.9	86
471	Uncontrolled hypertension and increased risk for incident heart failure in older adults with hypertension: findings from a propensity-matched prospective population study. Journal of the American Society of Hypertension, 2010, 4, 22-31.	2.3	58
472	Combination therapy in hypertension. Journal of the American Society of Hypertension, 2010, 4, 42-50.	2.3	173
473	Combination therapy in hypertension. Journal of the American Society of Hypertension, 2010, 4, 90-98.	2.3	156
474	Treatment of hypertension in patients with diabetesâ€™an update. Journal of the American Society of Hypertension, 2010, 4, 62-67.	2.3	12
475	Importance of blood pressure control in left ventricular mass regression. Journal of the American Society of Hypertension, 2010, 4, 302-310.	2.3	26
476	Renal outcomes with different fixed-dose combination therapies in patients with hypertension at high risk for cardiovascular events (ACCOMPLISH): a prespecified secondary analysis of a randomised controlled trial. Lancet, The, 2010, 375, 1173-1181.	6.3	472
477	Kidney Early Evaluation Program: A Community-Based Screening Approach to Address Disparities in Chronic Kidney Disease. Seminars in Nephrology, 2010, 30, 66-73.	0.6	47
478	Serum Creatinine vs. Albuminuria as Biomarkers for the Estimation of Cardiovascular Risk. Current Vascular Pharmacology, 2010, 8, 604-611.	0.8	14
479	Assessing Blood Pressure Control in Dialysis Patients. Hypertension, 2009, 53, 448-449.	1.3	6
480	Risk of Hyperkalemia in Nondiabetic Patients With Chronic Kidney Disease Receiving Antihypertensive Therapy<alt-title>Hyperkalemia in CKD Adults Using Antihypertensives</alt-title>. Archives of Internal Medicine, 2009, 169, 1587.	4.3	98
481	The Message for World Kidney Day 2009. Nephron Clinical Practice, 2009, 111, c155-c158.	2.3	0
482	The Message for World Kidney Day 2009. Kidney and Blood Pressure Research, 2009, 32, 67-70.	0.9	2
483	Hypertension Goals in Advanced-Stage Kidney Disease. Clinical Journal of the American Society of Nephrology: CJASN, 2009, 4, S92-S94.	2.2	9
484	The Message for World Kidney Day 2009. Blood Purification, 2009, 27, 231-234.	0.9	0
485	The Message for World Kidney Day 2009. American Journal of Nephrology, 2009, 30, 95-98.	1.4	14
486	Are Renin-Angiotensin-Aldosterone System Blockers Distinguishable Based on Cardiovascular and Renal Outcomes in Nephropathy?. Postgraduate Medicine, 2009, 121, 77-88.	0.9	6

#	ARTICLE	IF	CITATIONS
487	Monitoring and Managing Urinary Albumin Excretion: Practical Advice for Primary Care Clinicians. Postgraduate Medicine, 2009, 121, 51-60.	0.9	11
488	G-Protein-Coupled Receptor Kinase 4 Polymorphisms and Blood Pressure Response to Metoprolol Among African Americans: Sex-Specificity and Interactions. American Journal of Hypertension, 2009, 22, 332-338.	1.0	62
489	The message for World Kidney Day 2009: hypertension and kidney diseaseâ€”a marriage that should be prevented. Journal of Human Hypertension, 2009, 23, 222-225.	1.0	12
490	Predictors of Hyperkalemia Risk following Hypertension Control with Aldosterone Blockade. American Journal of Nephrology, 2009, 30, 418-424.	1.4	146
491	ADVANCE: Blood Pressure Lowering in Diabetes. Journal of Clinical Hypertension, 2009, 11, 109-110.	1.0	0
492	The Message for World Kidney Day 2009: Hypertension and Kidney Disease: A Marriage That Should Be Prevented. Journal of Clinical Hypertension, 2009, 11, 144-147.	1.0	28
493	Lower Blood Pressure Goals for Cardiovascular and Renal Risk Reduction: Are They Defensible?. Journal of Clinical Hypertension, 2009, 11, 345-347.	1.0	10
494	Pathogenesis and Treatment of Microalbuminuria in Patients With Diabetes: The Road Ahead. Journal of Clinical Hypertension, 2009, 11, 636-643.	1.0	30
495	The Editor's Roundtable: Prehypertension. American Journal of Cardiology, 2009, 104, 1105-1115.	0.7	1
496	Hypertension in Early-Stage Kidney Disease: An Update From the Kidney Early Evaluation Program (KEEP). American Journal of Kidney Diseases, 2009, 53, S22-S31.	2.1	30
497	World Kidney Day 2009: Hypertension and Kidney Disease Is a Marriage That Should Be Prevented. American Journal of Kidney Diseases, 2009, 53, 373-376.	2.1	9
498	The message for World Kidney Day 2009: hypertension and kidney diseaseâ€”a marriage that should be prevented. Clinical and Experimental Nephrology, 2009, 13, 96-99.	0.7	1
499	The current state of RAAS blockade in the treatment of hypertension and proteinuria. Current Cardiology Reports, 2009, 11, 436-442.	1.3	14
500	Glycemic control and cardiovascular disease in chronic kidney disease. Current Diabetes Reports, 2009, 9, 243-248.	1.7	10
501	Home blood pressure monitoring to manage hypertension in patients with nephropathy: The time has arrived. Current Hypertension Reports, 2009, 11, 299-300.	1.5	0
502	Hypertension guidelines and chronic kidney disease: Physicians, please follow directions. Current Hypertension Reports, 2009, 11, 301-302.	1.5	0
503	Risk factor assessment for new onset diabetes: literature review. Diabetes, Obesity and Metabolism, 2009, 11, 177-187.	2.2	31
504	Comparison of carvedilol and metoprolol on serum lipid concentration in diabetic hypertensive patients. Diabetes, Obesity and Metabolism, 2009, 11, 234-238.	2.2	49

#	ARTICLE	IF	CITATIONS
505	Management of hypertension in patients with diabetes: the place of angiotensinâ€”receptor blockers. <i>Diabetes, Obesity and Metabolism</i> , 2009, 11, 757-769.	2.2	19
506	A propensity-matched study of low serum potassium and mortality in older adults with chronic heart failure. <i>International Journal of Cardiology</i> , 2009, 137, 1-8.	0.8	43
507	Renal sodiumâ€”glucose transport: role in diabetes mellitus and potential clinical implications. <i>Kidney International</i> , 2009, 75, 1272-1277.	2.6	280
508	Hypertension and its Management in the Elderly. <i>Seminars in Nephrology</i> , 2009, 29, 604-609.	0.6	3
509	Treatment of hypertension in patients with diabetesâ€”an update. <i>Journal of the American Society of Hypertension</i> , 2009, 3, 150-155.	2.3	15
510	The message for World Kidney Day 2009: hypertension and kidney disease: a marriage that should be prevented. <i>Journal of the American Society of Hypertension</i> , 2009, 3, 80-83.	2.3	13
511	Is blockade of the renin-angiotensin system appropriate for all patients with diabetes?. <i>Journal of the American Society of Hypertension</i> , 2009, 3, 288-290.	2.3	2
512	A selective endothelin-receptor antagonist to reduce blood pressure in patients with treatment-resistant hypertension: a randomised, double-blind, placebo-controlled trial. <i>Lancet</i> , The, 2009, 374, 1423-1431.	6.3	277
513	The Kidney, Hypertension, and Remaining Challenges. <i>Medical Clinics of North America</i> , 2009, 93, 697-715.	1.1	43
514	Novel therapies of diabetic nephropathy. <i>Current Opinion in Nephrology and Hypertension</i> , 2009, 18, 107-111.	1.0	34
515	Should proteinuria reduction be the criterion for antihypertensive drug selection for patients with kidney disease?. <i>Current Opinion in Nephrology and Hypertension</i> , 2009, 18, 386-391.	1.0	22
516	The future of blood pressure control in a population with a growing girth. <i>Current Opinion in Nephrology and Hypertension</i> , 2009, 18, 379-380.	1.0	0
517	An In-depth Analysis of Vasodilation in the Management of Hypertension: Focus on Adrenergic Blockade. <i>Journal of Cardiovascular Pharmacology</i> , 2009, 53, 379-387.	0.8	35
518	Effects of angiotensin II receptor blockers on diabetic nephropathy. <i>Journal of Hypertension</i> , 2009, 27, S15-S21.	0.3	25
519	Response to â€”Telmisartan is more effective than losartan in reducing proteinuriaâ€”™. <i>Kidney International</i> , 2009, 75, 120.	2.6	0
520	The message for World Kidney Day 2009: hypertension and kidney disease â€” a marriage that should be prevented. <i>Journal of Hypertension</i> , 2009, 27, 666-669.	0.3	27
521	Effects of Thiazolidinediones Beyond Glycaemic Control. <i>Current Pharmaceutical Design</i> , 2009, 15, 529-536.	0.9	46
522	Does Evidence Support Reninâ€”Angiotensin System Blockade for Slowing Nephropathy Progression in Elderly Persons?. <i>Annals of Internal Medicine</i> , 2009, 150, 731.	2.0	20

#	ARTICLE	IF	CITATIONS
523	Inhibiting the renin-angiotensin system in patients with type 1 diabetes: is it worth it?. Polish Archives of Internal Medicine, 2009, 119, 692-693.	0.3	0
524	The message for World Kidney Day 2009: Hypertension and kidney disease: a marriage that should be prevented. Archives of Iranian Medicine, 2009, 12, 102-5.	0.2	0
525	Hypertension and kidney disease: a combination that should be prevented. Nephrology News & Issues, 2009, 23, 42, 44, 46.	0.1	0
526	The message for World Kidney Day 2009: hypertension and kidney disease, a marriage that should be prevented. Iranian Journal of Kidney Diseases, 2009, 3, 7-10.	0.1	1
527	Telmisartan is more effective than losartan in reducing proteinuria in patients with diabetic nephropathy. Kidney International, 2008, 74, 364-369.	2.6	135
528	Efficacy and Safety of Fixed Combinations of Irbesartan/Hydrochlorothiazide in Older vs Younger Patients With Hypertension Uncontrolled With Monotherapy. The American Journal of Geriatric Cardiology, 2008, 17, 27-36.	0.7	13
529	A Propensity-Matched Study of Hypertension and Increased Stroke-Related Hospitalization in Chronic Heart Failure. American Journal of Cardiology, 2008, 101, 1772-1776.	0.7	19
530	Race and Sex Differences in Hypertension Control in CKD: Results From the Kidney Early Evaluation Program (KEEP). American Journal of Kidney Diseases, 2008, 51, 192-198.	2.1	52
531	Hypertension and CKD: Kidney Early Evaluation Program (KEEP) and National Health and Nutrition Examination Survey (NHANES), 1999-2004. American Journal of Kidney Diseases, 2008, 51, S30-S37.	2.1	137
532	Prevalence and Associations of Anemia of CKD: Kidney Early Evaluation Program (KEEP) and National Health and Nutrition Examination Survey (NHANES) 1999-2004. American Journal of Kidney Diseases, 2008, 51, S46-S55.	2.1	95
533	Executive Summary: Kidney Early Evaluation Program (KEEP) 2007 Annual Data Report. American Journal of Kidney Diseases, 2008, 51, S1-S2.	2.1	147
534	CKD Awareness in the United States: The Kidney Early Evaluation Program (KEEP). American Journal of Kidney Diseases, 2008, 52, 382-383.	2.1	42
535	Demographic Analyses of the Effects of Carvedilol vs Metoprolol on Glycemic Control and Insulin Sensitivity in Patients With Type 2 Diabetes and Hypertension in the Glycemic Effects in Diabetes Mellitus: Carvedilol-Metoprolol Comparison in Hypertensives (GEMINI) Study. Journal of the Cardiometabolic Syndrome, 2008, 3, 211-217.	1.7	18
536	The Diabetes Subgroup Baseline Characteristics of the Avoiding Cardiovascular Events Through Combination Therapy in Patients Living With Systolic Hypertension (ACCOMPLISH) Trial. Journal of the Cardiometabolic Syndrome, 2008, 3, 229-233.	1.7	9
537	Reversal of Diuretic-Associated Impaired Glucose Tolerance and New-Onset Diabetes: Results of the STAR-LET Study. Journal of the Cardiometabolic Syndrome, 2008, 3, 18-25.	1.7	20
538	Challenges to the Diagnosis, Evaluation, Treatment, and Management of Clustered Cardiometabolic Risk Factors. Journal of the Cardiometabolic Syndrome, 2008, 3, 119-125.	1.7	0
539	ASH Position Paper: Treatment of Hypertension in Patients With Diabetes—An Update. Journal of Clinical Hypertension, 2008, 10, 707-713.	1.0	49
540	State of Hypertension Management in the United States: Confluence of Risk Factors and the Prevalence of Resistant Hypertension. Journal of Clinical Hypertension, 2008, 10, 130-139.	1.0	97

#	ARTICLE	IF	CITATIONS
541	Newer Combination Therapies in the Management of Hypertension: An Update. <i>Journal of Clinical Hypertension</i> , 2008, 10, 398-405.	1.0	3
542	Combination Therapy With Renin-Angiotensin-Aldosterone Receptor Blockers for Hypertension: How Far Have We Come?. <i>Journal of Clinical Hypertension</i> , 2008, 10, 146-152.	1.0	21
543	Î ² -Blockers in the Treatment of Hypertension: New Data, New Directions. <i>Journal of Clinical Hypertension</i> , 2008, 10, 234-238.	1.0	7
544	Comparative Efficacy of Two Different Î ² -Blockers on 24-Hour Blood Pressure Control. <i>Journal of Clinical Hypertension</i> , 2008, 10, 112-118.	1.0	13
545	A Comparative Evaluation of Various Methods for Microalbuminuria Screening. <i>American Journal of Nephrology</i> , 2008, 28, 324-329.	1.4	36
546	Beta-Blocker Therapy in Hypertension: A Need to Pause and Reflect. <i>Journal of the American College of Cardiology</i> , 2008, 51, 516-517.	1.2	2
547	Resistant Hypertension. <i>Journal of the American College of Cardiology</i> , 2008, 52, 1749-1757.	1.2	304
548	The pathogenesis of diabetic nephropathy. <i>Nature Clinical Practice Endocrinology and Metabolism</i> , 2008, 4, 444-452.	2.9	498
549	Chronic kidney disease, prevalence of premature cardiovascular disease, and relationship to short-term mortality. <i>American Heart Journal</i> , 2008, 156, 277-283.	1.2	160
550	Hypertension Awareness, Treatment, and Control in Chronic Kidney Disease. <i>American Journal of Medicine</i> , 2008, 121, 332-340.	0.6	250
551	Benazepril plus Amlodipine or Hydrochlorothiazide for Hypertension in High-Risk Patients. <i>New England Journal of Medicine</i> , 2008, 359, 2417-2428.	13.9	1,849
552	Blood Pressure Control in the Patient With Difficult-to-Control Hypertension: Which Agent for Which Patient?. <i>Preventive Cardiology</i> , 2008, 11, 42-49.	1.1	3
553	Combined Therapy With a Calcium Channel Blocker and an Angiotensin II Type 1 Receptor Blocker. <i>Journal of Clinical Hypertension</i> , 2008, 10, 27-32.	1.0	44
554	Renin-angiotensin blockade and kidney disease. <i>Lancet</i> , 2008, 372, 511-512.	6.3	51
555	Changes in Kidney Function Following Heart Failure Treatment: Focus on Renin-Angiotensin System Blockade. <i>Heart Failure Clinics</i> , 2008, 4, 425-438.	1.0	10
556	Renal Hemodynamic Changes in Heart Failure. <i>Heart Failure Clinics</i> , 2008, 4, 411-423.	1.0	20
557	Predictors of blood pressure response to intensified and fixed combination treatment of hypertension: The ACCOMPLISH Study. <i>Blood Pressure</i> , 2008, 17, 7-17.	0.7	49
558	Serum Potassium and Clinical Outcomes in the Eplerenone Post-acute Myocardial Infarction Heart Failure Efficacy and Survival Study (EPHESUS). <i>Circulation</i> , 2008, 118, 1643-1650.	1.6	209

#	ARTICLE	IF	CITATIONS
559	Should nephrologists use beta-blockers? A perspective. <i>Nephrology Dialysis Transplantation</i> , 2008, 24, 701-702.	0.4	15
560	Thiazide-Induced Dysglycemia. <i>Hypertension</i> , 2008, 52, 30-36.	1.3	105
561	Slowing Nephropathy Progression. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2008, 3, S3-S10.	2.2	103
562	Mechanistic Insights into Diuretic-Induced Insulin Resistance. <i>Hypertension</i> , 2008, 52, 1009-1011.	1.3	30
563	Calcium antagonists: Do they equally protect against kidney injury?. <i>Kidney International</i> , 2008, 73, 795-796.	2.6	16
564	Long-term Effects of Renin-Angiotensin System Blocking Therapy and a Low Blood Pressure Goal on Progression of Hypertensive Chronic Kidney Disease in African Americans. <i>Archives of Internal Medicine</i> , 2008, 168, 832.	4.3	149
565	Comparison of Dual RAAS Blockade and Higher-Dose RAAS Inhibition on Nephropathy Progression. <i>Postgraduate Medicine</i> , 2008, 120, 33-42.	0.9	15
566	Effects of different ACE inhibitor combinations on albuminuria: results of the GUARD study. <i>Kidney International</i> , 2008, 73, 1303-1309.	2.6	147
567	The message for World Kidney Day 2009: Hypertension and kidney disease: a marriage that should be prevented. <i>Nephrology Dialysis Transplantation</i> , 2008, 24, 695-697.	0.4	8
568	Response to Diuretics should be used as the second-line agent in combination with RAS inhibitors in proteinuric patients with CKD. <i>Kidney International</i> , 2008, 74, 1358-1359.	2.6	0
569	Influence of microalbuminuria in achieving blood pressure goals. <i>Current Opinion in Nephrology and Hypertension</i> , 2008, 17, 457-463.	1.0	16
570	Trials That Matter: The Effect of a Fixed-Dose Combination of an Angiotensin-Converting Enzyme Inhibitor and a Diuretic on the Complications of Type 2 Diabetes. <i>Annals of Internal Medicine</i> , 2008, 148, 400.	2.0	5
571	Appropriate dose transition to a controlled-release formulation of carvedilol in patients with hypertension. <i>Reviews in Cardiovascular Medicine</i> , 2008, 9, 96-105.	0.5	0
572	Should a lower blood pressure goal and albuminuria reduction be mandated to slow hypertensive nephropathy?. <i>Current Hypertension Reports</i> , 2008, 10, 387-8.	1.5	0
573	Albuminuria reduction and nephropathy progression. <i>Current Hypertension Reports</i> , 2008, 10, 388-9.	1.5	2
574	Validity and reproducibility of HOMA-IR, 1/HOMA-IR, QUICKI and McAuley's indices in patients with hypertension and type II diabetes. <i>Journal of Human Hypertension</i> , 2007, 21, 709-716.	1.0	150
575	The kidney and cardiovascular risk Implications for management: A consensus statement from the European Society of Hypertension. <i>Blood Pressure</i> , 2007, 16, 72-79.	0.7	24
576	Independent Components of Chronic Kidney Disease as a Cardiovascular Risk State. <i>Archives of Internal Medicine</i> , 2007, 167, 1122.	4.3	197

#	ARTICLE	IF	CITATIONS
577	Is it Time for a Cardiovascular Primary Prevention Trial in the Elderly?. <i>Stroke</i> , 2007, 38, 441-450.	1.0	55
578	The Antinatriuretic Effect of Insulin: An Unappreciated Mechanism for Hypertension Associated with Insulin Resistance?. <i>American Journal of Nephrology</i> , 2007, 27, 44-54.	1.4	70
579	Insulin and Endothelin: An Interplay Contributing to Hypertension Development?. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2007, 92, 379-385.	1.8	92
580	Primary Prevention of Cardiovascular Diseases in People With Diabetes Mellitus. <i>Circulation</i> , 2007, 115, 114-126.	1.6	634
581	Exceptional early blood pressure control rates: The ACCOMPLISH trial. <i>Blood Pressure</i> , 2007, 16, 80-86.	0.7	114
582	Blood Pressure Control and Improved Cardiovascular Outcomes in the International Verapamil SR-Trandolapril Study. <i>Hypertension</i> , 2007, 50, 299-305.	1.3	174
583	Protein Kinase C- β Inhibition: A Promise Not Yet Fulfilled. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2007, 2, 619-620.	2.2	6
584	Effect of Ruboxistaurin on Urinary Transforming Growth Factor- β in Patients With Diabetic Nephropathy and Type 2 Diabetes. <i>Diabetes Care</i> , 2007, 30, 995-996.	4.3	50
585	Dual Therapy in Hypertensive Patients with Coronary Artery Disease: The Role of Calcium Channel Blockers and β -Blockers. <i>American Journal of Cardiovascular Drugs</i> , 2007, 7, 25-29.	1.0	3
586	Improving Blood Pressure Control Rates: Is There More We Can Do?. <i>Journal of Clinical Hypertension</i> , 2007, 9, 134-142.	1.0	6
587	Microalbuminuria: What Is It? Why Is It Important? What Should Be Done About It? An Update. <i>Journal of Clinical Hypertension</i> , 2007, 9, 196-200.	1.0	39
588	Amlodipine and Valsartan Combined and as Monotherapy in Stage 2, Elderly, and Black Hypertensive Patients: Subgroup Analyses of 2 Randomized, Placebo-Controlled Studies. <i>Journal of Clinical Hypertension</i> , 2007, 9, 355-364.	1.0	85
589	ACE Inhibitors and ARBs: Are They Better Than Other Agents to Slow Nephropathy Progression?. <i>Journal of Clinical Hypertension</i> , 2007, 9, 413-415.	1.0	4
590	Efficacy and Safety of Darusentan in Patients With Resistant Hypertension: Results From a Randomized, Double-blind, Placebo-controlled Dose-ranging Study. <i>Journal of Clinical Hypertension</i> , 2007, 9, 760-769.	1.0	88
591	Lowering Blood Pressure With β -Blockers in Combination With Other Renin-Angiotensin System Blockers in Patients With Hypertension and Type 2 Diabetes: Results From the GEMINI Trial. <i>Journal of Clinical Hypertension</i> , 2007, 9, 842-849.	1.0	18
592	Body Weight Changes with β -Blocker Use: Results from GEMINI. <i>American Journal of Medicine</i> , 2007, 120, 610-615.	0.6	95
593	Non-esterified fatty acids and blood pressure elevation: a mechanism for hypertension in subjects with obesity/insulin resistance?. <i>Journal of Human Hypertension</i> , 2007, 21, 12-19.	1.0	81
594	Baseline characteristics in the Avoiding Cardiovascular events through Combination therapy in Patients Living with Systolic Hypertension (ACCOMPLISH) trial: A hypertensive population at high cardiovascular risk. <i>Blood Pressure</i> , 2007, 16, 13-19.	0.7	65

#	ARTICLE	IF	CITATIONS
595	Prevalence of abnormal serum vitamin D, PTH, calcium, and phosphorus in patients with chronic kidney disease: Results of the study to evaluate early kidney disease. <i>Kidney International</i> , 2007, 71, 31-38.	2.6	1,244
596	Treatment of microalbuminuria in hypertensive subjects with elevated cardiovascular risk: Results of the IMPROVE trial. <i>Kidney International</i> , 2007, 72, 879-885.	2.6	93
597	Should β -Blockers Be Used to Control Hypertension in People With Chronic Kidney Disease?. <i>Seminars in Nephrology</i> , 2007, 27, 555-564.	0.6	32
598	Primary Prevention of Cardiovascular Diseases in People With Diabetes Mellitus: A scientific statement from the American Heart Association and the American Diabetes Association. <i>Diabetes Care</i> , 2007, 30, 162-172.	4.3	577
599	Are antihypertensive drugs associated with an increased risk of incident type 2 diabetes?. <i>Nature Clinical Practice Endocrinology and Metabolism</i> , 2007, 3, 8-9.	2.9	1
600	β -Blocker use and diabetes symptom score: results from the GEMINI study. <i>Diabetes, Obesity and Metabolism</i> , 2007, 9, 408-417.	2.2	27
601	Differential effect of β -blocker therapy on insulin resistance as a function of insulin sensitizer use: results from GEMINI. <i>Diabetic Medicine</i> , 2007, 24, 759-763.	1.2	29
602	Chronic Kidney Disease Associated Mortality in Diastolic Versus Systolic Heart Failure: A Propensity Matched Study—The Digitalis Investigation Group study was conducted and supported by the National Heart, Lung, and Blood Institute in collaboration with the Digitalis Investigation Group Investigators. This manuscript was prepared using a limited access data set obtained by the National Heart, Lung, and Blood Institute and does not necessarily reflect the opinions or views of the Digitalis Investigation Gro. <i>American Journal of Cardiology</i> , 2007, 99, 393-398.	0.7	217
603	The Editor's Roundtable: Revisiting the Role of Beta Blockers in Hypertension. <i>American Journal of Cardiology</i> , 2007, 100, 253-267.	0.7	4
604	The Cardiometabolic Syndrome and Calcium Channel Blocker Combination Drugs. <i>Journal of the Cardiometabolic Syndrome</i> , 2007, 2, 207-212.	1.7	5
605	An Evidence-Based Practice Protocol for the Diagnosis and Management of Microalbuminuria in the Diabetic Patient. <i>Journal for Nurse Practitioners</i> , 2007, 3, 172-177.	0.4	0
606	Antihypertensive Therapy in the Presence of Proteinuria. <i>American Journal of Kidney Diseases</i> , 2007, 49, 12-26.	2.1	671
607	Antihypertensive agents, insulin sensitivity, and new-onset diabetes. <i>Current Diabetes Reports</i> , 2007, 7, 191-199.	1.7	42
608	Lifestyle changes and unanswered questions about hypertension and cardiovascular risk. <i>Current Hypertension Reports</i> , 2007, 9, 392-392.	1.5	0
609	Should all patients with type 2 diabetes receive initial combination therapy: an assessment of the ADVANCE trial. <i>Polish Archives of Internal Medicine</i> , 2007, 117, 389-390.	0.3	0
610	Cost-effectiveness of losartan in diabetic nephropathy: a Greek perspective. <i>Journal of Nephrology</i> , 2007, 20, 703-15.	0.9	6
611	Thiazide Diuretics, Potassium, and the Development of Diabetes. <i>Hypertension</i> , 2006, 48, 219-224.	1.3	405
612	Insulin Resistance, Hyperinsulinemia, and Hypertension: An Epidemiologic Approach. <i>Journal of the Cardiometabolic Syndrome</i> , 2006, 1, 334-344.	1.7	16

#	ARTICLE	IF	CITATIONS
613	Albuminuria and Cardiovascular Risk. Heart Failure Clinics, 2006, 2, 53-59.	1.0	2
614	Microalbuminuria. Clinics in Laboratory Medicine, 2006, 26, 635-653.	0.7	56
615	Measuring the efficacy of antihypertensive therapy by ambulatory blood pressure monitoring in the primary care setting. American Heart Journal, 2006, 151, 176-184.	1.2	58
616	Do the Metabolic Effects of β Blockers Make Them Leading or Supporting Antihypertensive Agents in the Treatment of Hypertension?. Journal of Clinical Hypertension, 2006, 8, 351-356.	1.0	21
617	Are β^2 Blockers Passable for the Treatment of Hypertension?. Journal of Clinical Hypertension, 2006, 8, 239-240.	1.0	4
618	An Effectiveness Study Comparing Algorithm-Based Antihypertensive Therapy With Previous Treatments Using Conventional and Ambulatory Blood Pressure Measurements. Journal of Clinical Hypertension, 2006, 8, 241-252.	1.0	3
619	Antihypertensive Efficacy of Irbesartan/HCTZ in Men and Women With the Metabolic Syndrome and Type 2 Diabetes. Journal of Clinical Hypertension, 2006, 8, 470-480.	1.0	39
620	Efficacy and Safety of Coadministered Amlodipine and Atorvastatin in Patients With Hypertension and Dyslipidemia: Results of the AVALON Trial. Journal of Clinical Hypertension, 2006, 8, 571-583.	1.0	51
621	Efficacy of a Once-Daily Formulation of Carvedilol for the Treatment of Hypertension. Journal of Clinical Hypertension, 2006, 8, 840-849.	1.0	31
622	Rosiglitazone reduces microalbuminuria and blood pressure independently of glycemia in type 2 diabetes patients with microalbuminuria. Journal of Hypertension, 2006, 24, 2047-2055.	0.3	88
623	Development of explicit criteria to measure adherence to hypertension guidelines. Journal of Human Hypertension, 2006, 20, 426-433.	1.0	36
624	Rationale and design of a study to evaluate management of proteinuria in patients at high risk for vascular events: the IMPROVE trial. Journal of Human Hypertension, 2006, 20, 693-700.	1.0	5
625	Protection of the kidney by thiazolidinediones: An assessment from bench to bedside. Kidney International, 2006, 70, 1223-1233.	2.6	194
626	Beta blockers in the management of chronic kidney disease. Kidney International, 2006, 70, 1905-1913.	2.6	164
627	Gender disparity in outcomes of care and management for diabetes and the metabolic syndrome. Current Diabetes Reports, 2006, 6, 219-224.	1.7	42
628	Clinical trials report. Current Hypertension Reports, 2006, 8, 395-397.	1.5	0
629	Obesity and Insulin Resistance As Risk Factors for Chronic Kidney Disease. Journal of the Cardiometabolic Syndrome, 2006, 1, 209-216.	1.7	24
630	Predictors of Development of Diabetes Mellitus in Patients With Coronary Artery Disease Taking Antihypertensive Medications (Findings from the International Verapamil SR-Trandolapril Study)	1.0	10

#	ARTICLE	IF	CITATIONS
631	Controlled-Release Carvedilol in the Treatment of Essential Hypertension. American Journal of Cardiology, 2006, 98, 32-38.	0.7	30
632	Cardiovascular Risk Factors in Hypertension: Rationale and Design of Studies to Investigate the Effects of Controlled-Release Carvedilol on Regression of Left Ventricular Hypertrophy and Lipid Profile. American Journal of Cardiology, 2006, 98, 46-52.	0.7	9
633	Cardiometabolic Syndrome and Chronic Kidney Disease: What Is the Link?. Journal of the Cardiometabolic Syndrome, 2006, 1, 58-65.	1.7	43
634	An In-Depth Review of the Evidence Linking Dietary Salt Intake and Progression of Chronic Kidney Disease. American Journal of Nephrology, 2006, 26, 268-275.	1.4	105
635	Microalbuminuria and chronic kidney disease as risk factors for cardiovascular disease. Nephrology Dialysis Transplantation, 2006, 21, 2366-2374.	0.4	100
636	Antihypertensive treatment with beta-blockers and the spectrum of glycaemic control. QJM - Monthly Journal of the Association of Physicians, 2006, 99, 431-436.	0.2	66
637	The Role of Hyperglycaemia and the Hypercoagulable State in the Pathogenesis of Cardiovascular Events in Diabetes Mellitus: Implications for Hypertension Management. Current Pharmaceutical Design, 2006, 12, 1567-1579.	0.9	12
638	Level of Kidney Function Determines Cardiovascular Fate After Coronary Bypass Graft Surgery. Circulation, 2006, 113, 1046-1047.	1.6	21
639	Lessons Learned from Recent Hypertension Trials about Kidney Disease. Clinical Journal of the American Society of Nephrology: CJASN, 2006, 1, 229-235.	2.2	41
640	Differences in Glucose Tolerance Between Fixed-Dose Antihypertensive Drug Combinations in People With Metabolic Syndrome. Diabetes Care, 2006, 29, 2592-2597.	4.3	175
641	Irbesartan/HCTZ fixed combinations in patients of different racial/ethnic groups with uncontrolled systolic blood pressure on monotherapy. Journal of the National Medical Association, 2006, 98, 618-26.	0.6	25
642	Antihypertensive Therapy and the Risk of New-Onset Diabetes. Diabetes Care, 2006, 29, 1167-1169.	4.3	11
643	Ambulatory blood pressure monitoring in the primary care setting: assessment of therapy on the circadian variation of blood pressure from the MICCAT-2 Trial. Blood Pressure Monitoring, 2005, 10, 157-163.	0.4	37
644	Higher prevalence of anemia with diabetes mellitus in moderate kidney insufficiency: The Kidney Early Evaluation Program. Kidney International, 2005, 67, 1483-1488.	2.6	145
645	Rationale and design of a study comparing two fixed-dose combination regimens to reduce albuminuria in patients with type II diabetes and hypertension. Journal of Human Hypertension, 2005, 19, 139-144.	1.0	5
646	The rationale and design of the Glycemic Effects in Diabetes Mellitus. Journal of Diabetes and Its Complications, 2005, 19, 74-79.	1.2	19
647	Proteinuria and Blood Pressure Reduction:. Current Hypertension Reports, 2005, 7, 357-358.	1.5	3
648	Does dietary salt increase the risk for progression of kidney disease?. Current Hypertension Reports, 2005, 7, 385-391.	1.5	21

#	ARTICLE	IF	CITATIONS
649	Calcium Antagonists. <i>Hypertension</i> , 2005, 46, 637-642.	1.3	62
650	Angiotensin receptor blockers: Therapeutic targets and cardiovascular protection. <i>Blood Pressure</i> , 2005, 14, 196-209.	0.7	67
651	The Effect of Ruboxistaurin on Nephropathy in Type 2 Diabetes. <i>Diabetes Care</i> , 2005, 28, 2686-2690.	4.3	283
652	The Relationship Between Magnitude of Proteinuria Reduction and Risk of End-stage Renal Disease. <i>Archives of Internal Medicine</i> , 2005, 165, 947.	4.3	264
653	Evaluating the Cardiovascular Effects of the Thiazolidinediones and Their Place in the Management of Type 2 Diabetes in Relation to the Metabolic Syndrome. <i>Metabolic Syndrome and Related Disorders</i> , 2005, 3, 147-173.	0.5	3
654	Association of NEDD4L Ubiquitin Ligase With Essential Hypertension. <i>Hypertension</i> , 2005, 46, 488-491.	1.3	72
655	Proteinuria. <i>Hypertension</i> , 2005, 46, 473-474.	1.3	18
656	Angiotensin Receptor Blockade and Arterial Compliance in Chronic Kidney Disease: A Pilot Study. <i>American Journal of Nephrology</i> , 2005, 25, 393-399.	1.4	17
657	Hypertension Treatment Guidelines: Practical Implications. <i>Seminars in Nephrology</i> , 2005, 25, 198-209.	0.6	9
658	Differential Effects of β -Blockers on Albuminuria in Patients With Type 2 Diabetes. <i>Hypertension</i> , 2005, 46, 1309-1315.	1.3	76
659	Effect of Fixed-Dose ACE-Inhibitor/Calcium Channel Blocker Combination Therapy vs. ACE-Inhibitor Monotherapy on Arterial Compliance in Hypertensive Patients With Type 2 Diabetes. <i>Preventive Cardiology</i> , 2005, 8, 87-92.	1.1	20
660	The Efficacy and Safety of Low- and High- Dose Fixed Combinations of Irbesartan/Hydrochlorothiazide in Patients With Uncontrolled Systolic Blood Pressure on Monotherapy: The INCLUSIVE Trial. <i>Journal of Clinical Hypertension</i> , 2005, 7, 578-586.	1.0	75
661	Control of Blood Pressure and Other Cardiovascular Risk Factors at Different Practice Settings: Outcomes of Care Provided to Diabetic Women Compared to Men. <i>Journal of Clinical Hypertension</i> , 2005, 7, 73-80.	1.0	49
662	Are Chlorthalidone and Hydrochlorothiazide Equivalent Blood-Pressure-Lowering Medications?. <i>Journal of Clinical Hypertension</i> , 2005, 7, 354-356.	1.0	49
663	Comparative Antihypertensive Efficacy of Angiotensin Receptor Blocker-Based Treatment in African-American and White Patients. <i>Journal of Clinical Hypertension</i> , 2005, 7, 587-597.	1.0	18
664	Preventing Hypertensive Kidney Disease: The Critical Role of Combination Therapy. <i>American Journal of Hypertension</i> , 2005, 18, 93-94.	1.0	5
665	Protecting renal function in the hypertensive patient: Clinical guidelines. <i>American Journal of Hypertension</i> , 2005, 18, 112-119.	1.0	25
666	Effects of Drospirenone/17- β Estradiol on Blood Pressure and Potassium Balance in Hypertensive Postmenopausal Women. <i>American Journal of Hypertension</i> , 2005, 18, 797-804.	1.0	72

#	ARTICLE	IF	CITATIONS
667	Physician adherence to JNC 7 guidelines and blood pressure control. American Journal of Hypertension, 2005, 18, A190-A190.	1.0	1
668	Differential Effects of β -Blockers on Albuminuria in Patients With Type 2 Diabetes. Hypertension, 2005, 46, 1309-1315.	1.3	1
669	Is ethnicity a factor in choice of antihypertensive drug?. Postgraduate Medicine, 2005, 117, 40.	0.9	0
670	Clinical trials report. Combination drug treatment for hypertension with nondiabetic renal disease. Current Hypertension Reports, 2005, 7, 358-9.	1.5	0
671	How to adjust ACE inhibitors and ARBs in diabetes?. Postgraduate Medicine, 2004, 115, 9-10.	0.9	1
672	Clinical Implications of Blockade of the Renin-Angiotensin System in Management of Hypertension. , 2004, 143, 105-116.		4
673	Blood Pressure Control and Nephroprotection in Diabetes. Journal of Clinical Pharmacology, 2004, 44, 431-438.	1.0	24
674	Clinical Outcomes in the Diabetes Cohort of the International Verapamil SR-Trandolapril Study. Hypertension, 2004, 44, 637-642.	1.3	114
675	When Does New Onset Diabetes Resulting From Antihypertensive Therapy Increase Cardiovascular Risk. Hypertension, 2004, 43, 941-942.	1.3	23
676	β -Blocker Use in Long-term Dialysis Patients. Archives of Internal Medicine, 2004, 164, 2465.	4.3	109
677	Diabetes and Chronic Kidney Disease: Tragedy and Challenge. Blood Purification, 2004, 22, 130-135.	0.9	10
678	Metabolic Effects of Carvedilol vs Metoprolol in Patients With Type 2 Diabetes Mellitus and Hypertension. JAMA - Journal of the American Medical Association, 2004, 292, 2227.	3.8	710
679	ImmunoDip [®] : An Improved Screening Method for Microalbuminuria. American Journal of Nephrology, 2004, 24, 284-288.	1.4	12
680	Effects of COX Inhibition on Blood Pressure and Kidney Function in ACE Inhibitor-Treated Blacks and Hispanics. Hypertension, 2004, 43, 573-577.	1.3	65
681	Differential effects of calcium antagonist subclasses on markers of nephropathy progression. Kidney International, 2004, 65, 1991-2002.	2.6	189
682	Inclusion of albuminuria in hypertension and heart guidelines. Kidney International, 2004, 66, S124-S125.	2.6	11
683	Management of hypertension in the cardiometabolic syndrome and diabetes. Current Diabetes Reports, 2004, 4, 199-205.	1.7	2
684	Clinical importance of microalbuminuria in diabetes and hypertension. Current Hypertension Reports, 2004, 6, 352-356.	1.5	43

#	ARTICLE	IF	CITATIONS
685	Is proteinuria a plausible target of therapy?. <i>Current Hypertension Reports</i> , 2004, 6, 177-181.	1.5	23
686	Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in chronic renal disease: safety issues. <i>Seminars in Nephrology</i> , 2004, 24, 168-175.	0.6	63
687	Rationale and design of the avoiding cardiovascular events through combination therapy in patients living with systolic hypertension (ACCOMPLISH) trialThe first randomized controlled trial to compare the clinical outcome effects of first-line combination therapies in hypertension. <i>American Journal of Hypertension</i> , 2004, 17, 793-801.	1.0	30
688	Slowing the progression of diabetic nephropathy and its cardiovascular consequences. <i>American Heart Journal</i> , 2004, 148, 243-251.	1.2	32
689	Treatment of hypertension in patients with diabetes mellitus: initial losartan/hydrochlorothiazide combination versus ramipril monotherapy. <i>American Journal of Hypertension</i> , 2004, 17, S106-S107.	1.0	0
690	Greater efficacy of chlorthalidone over hydrochlorothiazide for achieving blood pressure goals. <i>American Journal of Hypertension</i> , 2004, 17, S114.	1.0	1
691	Selection of explicit criteria for a JNC-7 guideline adherence tool. <i>American Journal of Hypertension</i> , 2004, 17, S144.	1.0	1
692	Effects of drospirenone/estradiol on blood pressure and serum potassium in hypertensive postmenopausal women at risk for hyperkalemia. <i>American Journal of Hypertension</i> , 2004, 17, S162.	1.0	0
693	Optimizing target-organ protection in patients with renal impairment. <i>American Journal of Hypertension</i> , 2004, 17, S246-S247.	1.0	0
694	Amlodipine/benazepril combination therapy for hypertensive patients nonresponsive to benazepril monotherapy. <i>American Journal of Hypertension</i> , 2004, 17, 590-596.	1.0	23
695	Rationale and design of the avoiding cardiovascular events through combination therapy in patients living with systolic hypertension (ACCOMPLISH) trial: the first randomized controlled trial to compare the clinical outcome effects of first-line combination therapies in hypertension. <i>American Journal of Hypertension</i> , 2004, 17, 793-801.	1.0	97
696	Advanced glycation end-product cross-link breakersA novel approach to cardiovascular pathologies related to the aging process. <i>American Journal of Hypertension</i> , 2004, 17, S23-S30.	1.0	180
697	The importance of blood pressure control in the patient with diabetes. <i>American Journal of Medicine</i> , 2004, 116, 30-38.	0.6	89
698	The JNC 7 Approach Compared to Conventional Treatment in Diabetic Patients With Hypertension: A Double-Blind Trial of Initial Monotherapy vs. Combination Therapy. <i>Journal of Clinical Hypertension</i> , 2004, 6, 437-442.	1.0	12
699	Implications of Albuminuria on Kidney Disease Progression. <i>Journal of Clinical Hypertension</i> , 2004, 6, 18-22.	1.0	14
700	Comparison of Commonly Used Assays for the Detection of Microalbuminuria. <i>Journal of Clinical Hypertension</i> , 2004, 6, 8-12.	1.0	47
701	The role of calcium antagonists in chronic kidney disease. <i>Current Opinion in Nephrology and Hypertension</i> , 2004, 13, 155-161.	1.0	23
702	How high should an ACE inhibitor or angiotensin receptor blocker be dosed in patients with diabetic nephropathy?. <i>Current Hypertension Reports</i> , 2003, 5, 418-425.	1.5	26

#	ARTICLE	IF	CITATIONS
703	Are antihypertensive drugs used to maximally reduce cardiovascular risk in dialysis patients?. American Journal of Kidney Diseases, 2003, 42, 1301-1304.	2.1	3
704	Heart failure as a cause for hospitalization in chronic dialysis patients. American Journal of Kidney Diseases, 2003, 41, 1267-1277.	2.1	129
705	Proteinuria and other markers of chronic kidney disease: a position statement of the national kidney foundation (NKF) and the national institute of diabetes and digestive and kidney diseases (NIDDK). American Journal of Kidney Diseases, 2003, 42, 617-622.	2.1	395
706	Achieving Goal Blood Pressure in Patients With Type 2 Diabetes: Conventional Versus Fixed-Dose Combination Approaches. Journal of Clinical Hypertension, 2003, 5, 202-209.	1.0	82
707	Who Should Be Treated With Combination Therapy as Initial Treatment for Hypertension?. Journal of Clinical Hypertension, 2003, 5, 21-28.	1.0	4
708	Defining the antihypertensive properties of the angiotensin receptor blocker telmisartan by a practice-based clinical trial. American Journal of Hypertension, 2003, 16, 460-466.	1.0	18
709	Role for β -blockers in the management of diabetic kidney disease. American Journal of Hypertension, 2003, 16, 7-12.	1.0	23
710	The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure<SUBTITLE>The JNC 7 Report</SUBTITLE>. JAMA - Journal of the American Medical Association, 2003, 289, 2560.	3.8	18,097
711	Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension, 2003, 42, 1206-1252.	1.3	11,852
712	A Calcium Antagonist vs a Non- β -Calcium Antagonist Hypertension Treatment Strategy for Patients With Coronary Artery Disease. JAMA - Journal of the American Medical Association, 2003, 290, 2805.	3.8	1,107
713	Effects of Blood Pressure Level on Progression of Diabetic Nephropathy<subtitle>Results From the RENAAL Study</subtitle>. Archives of Internal Medicine, 2003, 163, 1555.	4.3	399
714	Kidney Failure and Cardiovascular Disease. Circulation, 2003, 108, e114-5.	1.6	10
715	When to refer patients to a nephrologist?. Postgraduate Medicine, 2003, 113, 11-11.	0.9	0
716	Blood pressure, antihypertensive therapy and risk for renal injury in African-Americans. Current Opinion in Nephrology and Hypertension, 2003, 12, 79-84.	1.0	8
717	The evolution of treatment guidelines for diabetic nephropathy. Postgraduate Medicine, 2003, 113, 35-50.	0.9	4
718	Best diagnostic approach to hyperkalemia?. Postgraduate Medicine, 2003, 114, 64-64.	0.9	0
719	Microalbuminuria: marker of vascular dysfunction, risk factor for cardiovascular disease. Vascular Medicine, 2002, 7, 35-43.	0.8	244
720	Impact of an ACE inhibitor and calcium antagonist on microalbuminuria and lipid subfractions in type 2 diabetes: a randomised, multi-centre pilot study. Journal of Human Hypertension, 2002, 16, 185-191.	1.0	43

#	ARTICLE	IF	CITATIONS
721	Effect of Blood Pressure Lowering and Antihypertensive Drug Class on Progression of Hypertensive Kidney Disease <SUBTITLE> Results From the AASK Trial </SUBTITLE> . JAMA - Journal of the American Medical Association, 2002, 288, 2421.	3.8	1,792
722	Evaluation and Treatment of Patients With Systemic Hypertension. Circulation, 2002, 105, 2458-2461.	1.6	19
723	Orlistat improves blood pressure control in obese subjects with treated but inadequately controlled hypertension. Journal of Hypertension, 2002, 20, 2257-2267.	0.3	85
724	Barriers to blood pressure control in African Americans. Postgraduate Medicine, 2002, 112, 51-70.	0.9	31
725	Optimal treatment of hypertension in African Americans. Postgraduate Medicine, 2002, 112, 73-84.	0.9	6
726	Chapter 23 Treatment of the diabetic patient: focus on cardiovascular and renal risk reduction. Progress in Brain Research, 2002, 139, 289-298.	0.9	24
727	Type 2 Diabetes: RENAAL and IDNT-The Emergence of New Treatment Options. Journal of Clinical Hypertension, 2002, 4, 52-57.	1.0	44
728	Roundtable Discussion: Problems in the Management of Hypertension. Journal of Clinical Hypertension, 2002, 4, 207-212.	1.0	0
729	ACE Inhibitors and Protection Against Kidney Disease Progression in Patients With Type 2 Diabetes: What's the Evidence?. Journal of Clinical Hypertension, 2002, 4, 420-440.	1.0	30
730	A comparative trial of controlled-onset, extended-release verapamil, enalapril, and losartan on blood pressure and heart rate changes. American Journal of Hypertension, 2002, 15, 53-57.	1.0	37
731	Pathogenesis and clinical physiology of hypertension. Cardiology Clinics, 2002, 20, 195-206.	0.9	7
732	Renal handling of albumin: A critical review of basic concepts and perspective. American Journal of Kidney Diseases, 2002, 39, 899-919.	2.1	192
733	Microalbuminuria in diabetes: Focus on cardiovascular and renal risk reduction. Current Diabetes Reports, 2002, 2, 258-262.	1.7	9
734	Angiotensin converting enzyme inhibitors or angiotensin receptor blockers in nephropathy from type 2 diabetes. Current Hypertension Reports, 2002, 4, 185-190.	1.5	17
735	Treatment of hypertension in patients with renal disease. Cardiovascular Drugs and Therapy, 2002, 16, 503-510.	1.3	5
736	Microalbuminuria: What Is It? Why Is It Important? What Should Be Done about It?. Journal of Clinical Hypertension, 2001, 3, 99-102.	1.0	69
737	Antihypertensive Efficacy of Candesartan in Comparison to Losartan: The CLAIM Study. Journal of Clinical Hypertension, 2001, 3, 16-21.	1.0	49
738	Angiotensin-converting enzyme inhibition to enhance vascular health?clinical and research models. American Journal of Hypertension, 2001, 14, S264-S269.	1.0	16

#	ARTICLE	IF	CITATIONS
739	A Practical Approach to Achieving Recommended Blood Pressure Goals in Diabetic Patients. Archives of Internal Medicine, 2001, 161, 2661.	4.3	82
740	Choices and goals in the treatment of the diabetic hypertensive patient. Current Hypertension Reports, 2001, 3, 387-391.	1.5	2
741	Treatment of stage I hypertension and development of renal dysfunction. Journal of Human Hypertension, 2001, 15, 81-84.	1.0	6
742	Comparative Effects of Selective T- and L-Type Calcium Channel Blockers in the Remnant Kidney Model. Hypertension, 2001, 37, 1268-1272.	1.3	47
743	Effect of Ramipril vs Amlodipine on Renal Outcomes in Hypertensive Nephrosclerosis<SUBTITLE>A Randomized Controlled Trial</SUBTITLE>. JAMA - Journal of the American Medical Association, 2001, 285, 2719.	3.8	861
744	Hypertension in patients with diabetes. Postgraduate Medicine, 2000, 107, 29-38.	0.9	38
745	The Future of Clinical Trials in Chronic Renal Disease: Outcome of an NIH/FDA/Physician Specialist Conference. Journal of Clinical Pharmacology, 2000, 40, 815-825.	1.0	16
746	20th Century Advances in Clinical Pharmacology. Journal of Clinical Pharmacology, 2000, 40, 907-907.	1.0	0
747	Evolution of Drugs That Preserve Renal Function. Journal of Clinical Pharmacology, 2000, 40, 978-989.	1.0	5
748	Lack of evidence of blood pressure-independent protection by renin-angiotensin system blockade after renal ablation. Kidney International, 2000, 57, 1651-1661.	2.6	79
749	Responding to the challenge of diabetic nephropathy: the historic evolution of detection, prevention and management. Journal of Human Hypertension, 2000, 14, 667-685.	1.0	38
750	ACE inhibition or angiotensin receptor blockade: Impact on potassium in renal failure. Kidney International, 2000, 58, 2084-2092.	2.6	222
751	Therapeutic approaches to achieve desired blood pressure goals: focus on calcium channel blockers. Cardiovascular Drugs and Therapy, 2000, 14, 295-301.	1.3	38
752	New therapies in diabetes – thiazolidinediones. Expert Opinion on Emerging Drugs, 2000, 5, 441-456.	1.1	7
753	Hypertension in patients with diabetes. Postgraduate Medicine, 2000, 107, 53-64.	0.9	16
754	Antihypertensive Therapy and the Risk of Type 2 Diabetes Mellitus. New England Journal of Medicine, 2000, 342, 969-970.	13.9	125
755	Angiotensin-Converting Enzyme Inhibitor Associated Elevations in Serum Creatinine. Archives of Internal Medicine, 2000, 160, 685-93.	4.3	679
756	Comparison of Telmisartan vs. Valsartan in the Treatment of Mild to Moderate Hypertension Using Ambulatory Blood Pressure Monitoring. Journal of Clinical Hypertension, 2000, 5, 26-31.	1.0	11

#	ARTICLE	IF	CITATIONS
757	Preserving renal function in adults with hypertension and diabetes: A consensus approach. American Journal of Kidney Diseases, 2000, 36, 646-661.	2.1	1,314
758	Oral antidiabetic agents safe with renal disease?. Postgraduate Medicine, 2000, 107, 66.	0.9	0
759	Class differences in the effects of calcium channel blockers in the rat remnant kidney model. Kidney International, 1999, 55, 1849-1860.	2.6	97
760	Renal hemodynamics in radiocontrast medium-induced renal dysfunction: A role for dopamine-1 receptors. Kidney International, 1999, 56, 206-210.	2.6	117
761	Benefits of combination angiotensin- converting enzyme inhibitor and calcium antagonist therapy for diabetic patients. American Journal of Hypertension, 1999, 12, 80-85.	1.0	31
762	When to discontinue ACE inhibitors for nephropathy. Postgraduate Medicine, 1999, 106, 29-29.	0.9	0
763	Maximizing Cardiorenal Benefit in the Management of Hypertension: Achieve Blood Pressure Goals. Journal of Clinical Hypertension, 1999, 1, 141-147.	1.0	42
764	The Appropriate Blood Pressure Control in Diabetes (ABCD) Trial. Journal of Human Hypertension, 1998, 12, 653-655.	1.0	17
765	Differential effects of calcium channel blockers on size selectivity of proteinuria in diabetic glomerulopathy. Kidney International, 1998, 54, 889-896.	2.6	93
766	Effects of an ACE inhibitor/calcium antagonist combination on proteinuria in diabetic nephropathy. Kidney International, 1998, 54, 1283-1289.	2.6	246
767	The role of combination antihypertensive therapy and the progression of renal disease hypertensionLooking toward the next millennium. American Journal of Hypertension, 1998, 11, 158S-162S.	1.0	21
768	The Renin-Angiotensin System in Diabetic Nephropathy: The Endothelial Connection. Mineral and Electrolyte Metabolism, 1998, 24, 381-388.	1.1	22
769	Risks for renal involvement in diabetes. Postgraduate Medicine, 1998, 104, 33-33.	0.9	0
770	Treatment of renal failure and blood pressure. Current Opinion in Nephrology and Hypertension, 1997, 6, 237-242.	1.0	2
771	Calcium Antagonism Abolishes the Antipressor Action of Vasopressin (V1) Receptor Antagonism. American Journal of Hypertension, 1997, 10, 1153-1158.	1.0	4
772	Renal mortality associated with non-insulin-dependent diabetes mellitus. Journal of Diabetes and Its Complications, 1997, 11, 104-111.	1.2	1
773	Predictors of renal and cardiovascular mortality in patients with non-insulin-dependent diabetes: A brief overview of microalbuminuria and insulin resistance. Journal of Diabetes and Its Complications, 1997, 11, 352-357.	1.2	25
774	Effect of Calcium Channel or $\hat{1}^2$ -Blockade on the Progression of Diabetic Nephropathy in African Americans. Hypertension, 1997, 29, 744-750.	1.3	131

#	ARTICLE	IF	CITATIONS
775	Modifiable risk factors predicted the development of diabetic nephropathy. ACP Journal Club, 1997, 127, 17.	0.1	0
776	Therapeutic challenges in the obese diabetic patient with hypertension. American Journal of Medicine, 1996, 101, 33S-46S.	0.6	43
777	Salt intake and reductions in arterial pressure and proteinuria is there a direct link?. American Journal of Hypertension, 1996, 9, S200-S206.	1.0	22
778	Is the level of arterial pressure reduction important for preservation of renal function. Nephrology Dialysis Transplantation, 1996, 11, 2383-2384.	0.4	3
779	Effects of Dihydropyridine Calcium Antagonists on Albuminuria in Patients with Diabetes. Journal of Clinical Pharmacology, 1996, 36, 274-279.	1.0	28
780	Microalbuminuria: prognostic implications. Current Opinion in Nephrology and Hypertension, 1996, 5, 219-223.	1.0	63
781	Current Issues in Treating the Hypertensive Patient with Diabetes: Focus on Diabetic Nephropathy. Annals of Pharmacotherapy, 1996, 30, 791-801.	0.9	12
782	Effects of Sodium Intake on Albumin Excretion in Patients with Diabetic Nephropathy Treated with Long-Acting Calcium Antagonists. Annals of Internal Medicine, 1996, 125, 201.	2.0	79
783	Calcium channel blockers versus other antihypertensive therapies on progression of NIDDM associated nephropathy. Kidney International, 1996, 50, 1641-1650.	2.6	375
784	Symposium from the 1993 Annual Meeting of the American College of Clinical Pharmacology. Journal of Clinical Pharmacology, 1995, 35, 72-72.	1.0	0
785	Hypertension in Diabetic Patients: An Update of Interventional Studies to Preserve Renal Function. Journal of Clinical Pharmacology, 1995, 35, 73-80.	1.0	9
786	Renal effects of oral prostaglandin supplementation after ibuprofen in diabetic subjects: a double-blind, placebo-controlled, multicenter trial.. Journal of the American Society of Nephrology: JASN, 1995, 5, 1684-1688.	3.0	15
787	ACE inhibitor mediated reductions in renal size and microalbuminuria in normotensive, diabetic subjects. Journal of Diabetes and Its Complications, 1994, 8, 2-6.	1.2	63
788	Effects of different antihypertensive treatments on morphologic progression of diabetic nephropathy in uninephrectomized dogs. Kidney International, 1994, 46, 161-169.	2.6	98
789	Microalbuminuria and progressive renal disease. Journal of Human Hypertension, 1994, 8, 809-17.	1.0	12
790	Renal adaptation to the failing heart. Understanding the cascade of responses. Postgraduate Medicine, 1994, 95, 141-6, 149-50.	0.9	0
791	Captopril reduced progression of microalbuminuria in normotensive type 1 diabetes. ACP Journal Club, 1994, 121, 11.	0.1	0
792	Long-term effects of antihypertensive regimens on renal hemodynamics and proteinuria. Kidney International, 1993, 43, 1210-1218.	2.6	131

#	ARTICLE	IF	CITATIONS
793	Hypertension in Diabetic Patients An Overview of Interventional Studies to Preserve Renal Function. American Journal of Hypertension, 1993, 6, 140S-147S.	1.0	32
794	Severe Hypertension in a Young Patient. Hospital Practice (1995), 1993, 28, 47-54.	0.5	0
795	Angiotensin-Converting Enzyme Inhibitors and Progression of Diabetic Nephropathy. Annals of Internal Medicine, 1993, 118, 643.	2.0	43
796	The Medical Bookshelf. Postgraduate Medicine, 1993, 93, 14-14.	0.9	0
797	Drug dosing in patients with renal insufficiency. Postgraduate Medicine, 1993, 94, 153-164.	0.9	7
798	Renal Effects of Antihypertensive Medications: An Overview. Journal of Clinical Pharmacology, 1993, 33, 392-399.	1.0	8
799	Diabetic nephropathy. Postgraduate Medicine, 1993, 93, 89-100.	0.9	37
800	The Use of Antisense Oligonucleotides to Establish Autocrine Angiotensin Growth Effects in Human Neuroblastoma and Mesangial Cells. Antisense Research and Development, 1992, 2, 199-210.	3.3	18
801	Risk for renal injury in diabetic hypertensive patients. Postgraduate Medicine, 1992, 91, 77-84.	0.9	3
802	Treatment of arterial hypertension in diabetic humans: Importance of therapeutic selection. Kidney International, 1992, 41, 912-919.	2.6	203
803	Treatment of hypertension in the elderly: a review. Geriatric Nephrology and Urology, 1991, 1, 121-127.	0.4	1
804	Arginine vasopressin stimulates human mesangial cell production of endothelin.. Journal of Clinical Investigation, 1991, 87, 1158-1164.	3.9	66
805	The effects of calcium antagonists on renal hemodynamics, urinary protein excretion, and glomerular morphology in diabetic states.. Journal of the American Society of Nephrology: JASN, 1991, 2, S21.	3.0	21
806	Calcium antagonists. Current Opinion in Cardiology, 1990, 5, 633-634.	0.8	0
807	Acute Interstitial Nephritis with Glomerulopathy Due to Nonsteroidal Anti-inflammatory Agents: A Review of Its Clinical Spectrum and Effects of Steroid Therapy. Journal of Clinical Pharmacology, 1990, 30, 468-475.	1.0	51
808	The Effects of Enalapril on Urinary Protein Excretion in Patients with Idiopathic Membranous Nephropathy. Journal of Clinical Pharmacology, 1990, 30, 155-158.	1.0	4
809	Effects of Different Calcium Antagonists on Proteinuria Associated with Diabetes Mellitus. Annals of Internal Medicine, 1990, 113, 987.	2.0	137
810	Effects of Diltiazem or Lisinopril on Massive Proteinuria Associated with Diabetes Mellitus. Annals of Internal Medicine, 1990, 112, 707.	2.0	151

#	ARTICLE	IF	CITATIONS
811	Oxygen free radical involvement in urinary Tamm-Horsfall protein excretion after intrarenal injection of contrast medium.. Radiology, 1990, 175, 57-60.	3.6	42
812	Effects of Theophylline on Erythropoietin Production in Normal Subjects and in Patients with Erythrocytosis after Renal Transplantation. New England Journal of Medicine, 1990, 323, 86-90.	13.9	128
813	The evolution of antihypertensive therapy: An overview of four decades of experience. Journal of the American College of Cardiology, 1989, 14, 1595-1608.	1.2	30
814	Renal dysfunction resulting from NSAIDs. American Family Physician, 1989, 40, 199-204.	0.1	9
815	Comparison of the effects of dopamine and fenoldopam, a selective dopamine-1 agonist, on parathyroid hormone release in man. Mineral and Electrolyte Metabolism, 1988, 14, 343-6.	1.1	3
816	The renal, forearm, and hormonal responses to standing in the presence and absence of propranolol.. Circulation, 1986, 74, 1061-1065.	1.6	19
817	A role for calcium in radiocontrast-induced reductions in renal hemodynamics. Kidney International, 1985, 27, 465-468.	2.6	141
818	Pulmonary scar carcinoma a clinicopathologic analysis. Cancer, 1983, 52, 493-497.	2.0	36
819	Chronic pain. Postgraduate Medicine, 1983, 73, 119-128.	0.9	1
820	Choreoathetosis associated with lithium: case report and literature review. American Journal of Psychiatry, 1983, 140, 1621-1622.	4.0	19
821	Disopyramide-associated liver dysfunction. Mayo Clinic Proceedings, 1983, 58, 265-7.	1.4	6
822	Clonidine for opiate withdrawal. Postgraduate Medicine, 1982, 71, 240-241.	0.9	1
823	The use of clonidine for management of opiate abstinence in a chronic pain patient. Mayo Clinic Proceedings, 1982, 57, 657-60.	1.4	5
824	Lithium prophylaxis and the kidney. Journal of Affective Disorders, 1981, 3, 37-42.	2.0	6